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Cat́ia Teixeira,*,†, ‡ Nuno Vale,† Bianca Peŕez,† Ana Gomes,† Jose ́ R. B. Gomes, ‡ and Paula Gomes*,†
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1. INTRODUCTION
Malaria has been a human health concern ever since the dawn
of mankind, but despite the huge struggles made to date to fight
this infection, in 2012 over half a million people were killed and
a quarter billion got infected, in most cases by the Plasmodium
falciparum (P. falciparum) species.1 Antimalarial chemotherapy
has been based on an endless search for the next weapon to
strike Plasmodium parasites when they find their way to elude
the action of current drugs. New antimalarials should be low-
cost ones, or else they will hardly fit a realistic malaria
containment scenario. Given that one possible way to lower
overall costs in antimalarial drug development is to work on
already known therapeutic agents, the present review is focused
on efforts that have been made over the past 15 years to find
efficient and affordable antimalarials through recycling,
rescuing, or repurposing classical drugs.
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The World Health Organization’s (WHO) goal of having
reduced, by the end of 2015, (i) malaria deaths to near zero and
(ii) the number of new infections by 75% (from levels
registered in 2000) has triggered a worldwide crusade to fight
this disease: according to the WHO’s World Malaria Report
2013, “International disbursements to malaria-endemic coun-
tries have increased markedly, from less than US$ 100 million
in 2000 to US$ 1.6 billion in 2011, and an estimated US$ 1.94
billion in 2012 and 1.97 billion in 2013”.1 This was
accompanied by massive adhesion of Medicinal Chemists to
this campaign, with consequent proliferation of research
groups, and scientific publications, focused on antimalarial
chemotherapy. This focus has been such over the past decade
that malaria is no longer regarded as a neglected tropical disease
(NTD).2 Still, and again quoting the same WHO’s Malaria
Report, “This progress is no cause for complacency. The
absolute numbers of malaria cases and deaths are not going
down as fast as they could. The disease still took an estimated
627 000 lives in 2012, mostly those of children under five years
of age in Africa.1 The fact that so many people are dying from
mosquito bites is one of the greatest tragedies of the 21st
century”.1 One of the causes for such tragedy is the cost of first-
line treatments against chloroquine-resistant P. falciparum
malaria, such as artemisinin-based combination therapies
(ACT), which may be too high for most of the low-income
malaria-endemic countries.3 Such drug cost limitations underlie
an even darker perversity: fake and low-quality antimalarial
drug pipelines that undermine the recent progress in malaria
containment.4
The history of antimalarial chemotherapy has been a
wavering one: the world has recurrently witnessed the rise
and fall of drugs, whose originally thrilling antimalarial
properties eventually gave place to disappointing news about
previously undisclosed toxicity issues (e.g., quinine, pamaquine,
mepacrine, mefloquine) or, predominantly, emergence of
parasite resistance (e.g., chloroquine, mefloquine, sulfadoxine-
pyrimethamine). The spread of chloroquine-resistant P.
falciparum strains all around the globe was actually the most
devastating drawback of the 20th century in malaria control:
earlier regarded as an almost perfect antimalarial, given its
efficacy, safety (including for pregnants and newborns), good
pharmacokinetics and low cost, chloroquine also became a
“fallen angel” in antimalarial chemotherapy.5 Furthermore,
given the recent reports on artemisinin-resistant P. falciparum
strains that are emerging in Southeast Asia, it seems very likely
that the 21st century antimalarial “stars”, artemisinin and
derivatives, will soon follow the same trail.6
Antimalarial drug research has been, and must keep on being,
an endless search for the next weapon to strike the parasite
when it finds its way to elude the action of currently available
drugs. Ideally, the new drugs should be produced at low cost, or
else they will hardly fit a realistic malaria containment scenario.
In this sense, the “3 R’s of the Environment” might prove useful
in new antimalarial chemotherapy strategies: “Recycle, Reuse,
Reduce”. “Recycling” known drugs for malaria may be achieved
by (i) performing synthetically affordable chemical modifica-
tions on classical antimalarials, now dethroned by ACT, (ii)
repurposing drugs originally developed for other diseases, and
found to also display antimalarial activity, and (iii) developing
new combination therapies based on known drugs. This latter
approach benefits from the fact that it provides the antimalarial
drug arsenal with new chemical entities that have (i) core
structures already known to be active and [at least, reasonably]
bioavailable; (ii) already settled companies dedicated to large-
scale production of the core structures, for possible “Reuse”
with minor adaptations of the manufacture pipeline. This
would, in principle, “Reduce” overall drug production costs, as
compared to those required for setting up, from scratch, large-
scale production of a completely new compound. Reduced
costs would also be predictable at the preclinical development
level, as synthetic routes targeting the basic core are already
known. Recent examples support this view: e.g., a simplified
chloroquine analogue, AQ-13 (see section 5.1), reached phase
II clinical trials in July 2012.7 In this connection, this review will
mainly focus on efforts that have been made, from 2000
onward, to find alternatives for malaria treatment, through both
synthetic and/or computational approaches toward modifica-
tion of classical antimalarials, and repurposing of known drugs
for malaria chemotherapy.
2. CHEMICAL RECYCLING OF QUININE: THE RISE OF
EMBLEMATIC 20TH CENTURY ANTIMALARIALS
2.1. Quinine: Past, Present and Future
Much has been said and written about the earliest antimalarial
drug recognized as such, the alkaloid quinine (Q, Figure 1).
From the mid-19th century to the 1940s, Q became the
standard therapy for intermittent fever throughout the world,
but emergence of safer and more potent/bioavailable
antimalarials outdid Q’s role as an antimalarial from then on.8
Still, one of the strengths of Q is the fact that malaria parasites
are rather slow in developing resistance against this drug. In
fact, although Q’s use spread in Europe as early as in the
beginning of the 17th century, resistance to this drug was first
reported only in 1910.8 In contrast, resistance to proguanil
emerged within only one year after its introduction,9 while for
chloroquine resistance appeared after 12 years.10 A worrying
fact is that resistance to the 21st century antimalarial symbol,
artemisinin, seems to be also appearing in Southeast Asia.11
Hence, Q is still employed against malaria in the clinics, usually
as monotherapy, but also eventually combined with a second
Figure 1. (A) Hydroformylation of the cinchona alkaloids (from Q, 1,
2a and 2b); (B) reductive amination; and (C) reduction of aldehyde
3.16
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agent to shorten the duration of therapy and thus minimize Q’s
adverse effects.12
The search for suitable Q surrogates through modification of
the Cinchona alkaloids (Figure 1) continues to be addressed.
The total synthesis of Q was only achieved in 1944 by
Woodward and Doering,13 and remains quite laborious as well
as economically unviable as compared to its isolation from the
bark of Cinchona trees.14 Still, Q has been long the target of
numerous synthetic endeavors, including chemical modifica-
tions earlier focused on substitutions around the quinoline
moiety, as these seemed to be less detrimental for antimalarial
activity.15 Recent examples of chemical recycling of the Q’s
structure have also involved modification outside the quinoline
core; for example, Lambers et al. explored conversion of the
vinyl group common to all four naturally occurring cinchona
alkaloids (Figure 1) into a functional group that could be used
as a linker, such as a carboxylic acid or an aldehyde (3, Figure
1); the latter was further modified via either reductive
amination (4, Figure 1) or reduction to the corresponding
alcohol (5, Figure 1).16
Bhattacharjee et al. have put forth a catalyst-generated
binding model that indicates the vinyl group to be eventually
important for Q’s activity;17 however, Alumasa et al. have later
suggested that such group is nonessential for binding to
heme,15 the putative drug target of Q and other quinoline
antimalarials.18 In this connection, Dinio et al. pursued a
structure−activity relationship study through modification of
the vinyl group by use of the Heck reaction (6, Figure 2), which
yielded compounds with good antiplasmodial activity in Q-
resistant and Q-sensitive strains.19
There are other recent works on chemical modifications at
the Q’s vinyl group to produce novel Q analogues (e.g., 7,
Figure 3);20 however, to the best of our knowledge, their
antimalarial properties have not been reported so far.
A newest example of Medicinal Chemistry work around the
Q scaffold, by Sanders et al., has been inspired in
hydroxyethylapoquinine (8, Figure 4), which was introduced
as an antimalarial in the 1940s, allegedly to overcome
cardiotoxicity events associated with Q and quinidine. These
authors have synthesized and studied four compounds:
compound 8, its novel stereoisomer hydroxyethylapoquinidine
(9, Figure 4), and two synthetic intermediates, hydroxyethyl-
quinine (10) and hydroxyethylquinidine (11). The latter was
found to be the most interesting compound of the set, as it
inhibits heme crystallization in vitro, is comparable to Q against
human P. falciparum in vitro and against mouse P. berghei
ANKA in vivo, and does not appreciably inhibit hERG channels.
Hence, compound 11 seems to be an adequate lead for
developing a new class of Q-based antimalarials, on which
further chemical modifications should be pursued.21
Finally, an example that emerged in line with two of the
major 21st century keywords in antimalarial chemotherapy,
artemisinin and covalent bitherapy:22 Bell and co-workers
created an artemisinin/quinine conjugate (12, Figure 5)
Figure 2. New quinine derivatives (6) developed by Dinio et al.19
Figure 3. New Q derivatives developed by Garner and Koide (7).20b
Figure 4. New Q and quinidine derivatives developed by Sanders.21
Figure 5. Artemisinin/quinine conjugate (12) developed by Bell and
co-workers.23
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through coupling of dihydroartemisinin to a carboxylic acid
derivative of Q, via an ester linkage.23 Hybrid compounds
underlying the covalent bitherapy concept consist of a single
molecule that joins together, through a covalent bond, two
different pharmacological agents.24 This covalent bitherapy
strategy may offer a more effective way to deliver the agent, for
instance, diminishing drug−drug adverse interactions.25 The
novel hybrid molecule 12 was active against both sensitive and
resistant strains of P. falciparum in culture, and its activity was
superior to that of artemisinin or Q alone, or to a 1:1 mixture of
these two drugs.23
Despite recent promising findings on Q surrogates, none
seems to have been taken to clinical trials yet. Still, it is
foreseeable that Q will continue to play a significant role in the
management of malaria in the near future, particularly in
resource-limited settings.14
2.2. Quinine and the Birth of Major 20th Century
Antimalarial Drug Classes
Another, or perhaps the, major contribution of Q to the malaria
containment scenario has been its role, together with
methylene blue (MB, Figure 6), as cotemplates on which the
most emblematic antimalarial drugs of the 20th century have
been built. Following Paul Ehrlich’s pioneering use of MB to
cure malaria in two patients, in the late 19th century, a quest for
better antimalarial surrogates ofMB was headed by the German
chemical and pharmaceutical company, Bayer, until the end of
World War II (WWII). This led to the discovery, in the first
quarter of the 20th century, that MB’s antimalarial potency
could be raised by replacing one of the dye’s methyl groups
with a dialkylaminoalkyl chain to give compound 13 (Figure
6).26 Such findings triggered great efforts that led to the first
antimalarial drug of synthetic origin, pamaquine or plasmo-
quine (PM, Figure 6), an 8-aminoquinoline (8-AQ) where the
dialkylaminoalkyl chain was combined with the quinoline core
of Q.27 This discovery was soon followed by another relevant
one in 1931: quinacrine (QN, Figure 6), also known as
mepacrine or atabrine,28 which was of chief importance to
protect soldiers fighting in tropical regions during WWII.29
Only three years later, Bayer gave birth to what was going to
become the most emblematic antimalarial of the 20th century:
the 4-aminoquinoline (4-AQ) resochin, or chloroquine (CQ,
Figure 6), whose potency, bioavailability and safety outshined
those of all antimalarials available by then.30
Those three classical antimalarial drugs from Bayer
represented the rise of the three major classes of 20th century
antimalarials: 8-aminoquinolines, acridines and 4-aminoquino-
lines. The relevance of these three families of antimalarials is
still felt at present day, since many such compounds are still
used in the clinical setting, and also because medicinal chemists
worldwide keep up using their scaffolds as templates toward
creation of better drugs.
3. ANTIMALARIAL 8-AMINOQUINOLINES: STILL
SEEKING FOR A SUITABLE SUBSTITUTE OF
PRIMAQUINE
3.1. From Pamaquine to PrimaquineTargeting Parasite’s
Liver and Sexual Stages
As already mentioned in the previous section, the first synthetic
antimalarial drug that emerged from Bayer’s effort to find
substitutes for Q and MB was pamaquine (PM). This 8-
aminoquinoline (8-AQ) was found to be useful in the
prevention of infection relapses associated with dormant liver
forms (hypnozoites) of P. vivax and P. ovale species, the first of
which being the most prevalent outside Africa. Furthermore,
PM also acted as a transmission-blocking agent, i.e., was able to
impair the parasite’s sexual reproductive cycle in Anopheles
mosquitoes fed on the blood of infected mammals. However,
PM was quickly abandoned by clinicians due to its high toxicity
and limited activity against the prostrating and life-threatening
infective phase (blood stage) of P. falciparum malaria.31
The importance of having a drug in the clinics that targets
liver (both active and dormant forms) and sexual stages of
malaria parasites, in other words, having complementary action
to blood-stage drugs as QN or CQ, soon became obvious. Such
was further reinforced by the fact that, in 1941−45, U.S.
soldiers were fighting in P. vivax-endemic regions of the Pacific
and by the rising menace of war in Korea soon after its division
along the 38th parallel, in 1945. Therefore, by the end of
WWII, the U.S. Army was deeply engaged in the effort of
improving the therapeutic index of PM, participating in
academic-military partnerships that led to production of
hundreds of other 8-AQ that included pentaquine (14, Figure
7),32 isopentaquine (15, Figure 7),33 and primaquine (PQ,
Figure 7). It was soon perceived that, among all those 8-AQ,
only PQ, whose synthesis was reported by Elderfield in 1946,34
was of real clinical utility. Since 1950, PQ remains as the only
drug clinically approved worldwide for treatment of relapsing P.
vivax malaria (30 mg/day/7days).31
3.2. Primaquine-Based 8-Aminoquinolines in Specific
Clinical Settings or under Clinical Trials
PQ is associated with serious adverse effects as a consequence
of its toxic metabolites, such as 5-hydroxy-PQ (16, Figure 8) or
6-methoxy-8-AQ (17, Figure 8), which have been considered as
directly responsible for hematological complications such as
methemoglobinemia and hemolytic anemia. Also, PQ is rapidly
metabolized in mammals to carboxy-PQ (18, Figure 8), which
is devoid of significant antimalarial activity.35 Therefore, many
efforts were undertaken in the second half of the 20th century
Figure 6. Illustrated role of quinine (Q) and methylene blue (MB)
derivative (13) in the rise of the most emblematic classes of
antimalarial drugs of the 20th century: 8-aminoquinolines, represented
by pamaquine (PM), acridines, represented by quinacrine (QN), and
4-aminoquinolines, represented by chloroquine (CQ).
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aimed at improving the therapeutic properties of PQ-related
compounds.
Some such efforts culminated in PQ surrogates which, thus
far, have not been accepted for clinical use worldwide, but
either have been approved by national entities in some
countries or are currently under clinical trials. One such drug
is quinocide (19, Figure 9), an isomer of PQ that was
synthesized in the former Soviet Union in the late 1950s but
whose use worldwide use was blocked by the fact that it is more
toxic than PQ itself.36 India is another country that has been
long fostering important efforts toward development of safer
PQ surrogates to combat P. vivax malaria, mainly through its
Central Drug Research Institute (CDRI). A series of cyclic
enaminone analogues of PQ were prepared in CDRI as
prodrugs of PQ, among which bulaquine, also known as
elubaquine or aablaquine (20, Figure 9), was believed to be a
better alternative to PQ against P. vivax malaria.37 Several
studies with both PQ and bulaquine, in India and Thailand,
suggested the latter to be safer and more potent than the
former,38 for both prevention of relapse in P. vivax malaria37b,39
and as a gametocytocidal agent against P. falciparum (25 mg/
day/5 days).40
One of the most promising PQ derivatives, tafenoquine (21,
Figure 9),41 has successfully completed phase IIb clinical trials
by the end of 2013.42 Tafenoquine was developed in the U.S.
by researchers at the Walter Reed Army Institute of Research
(WRAIR) as soon as in 1963, and identified under the code
WR238605.43 Originally, tafenoquine was investigated as a
substitute for PQ for radical cure of P. vivax malaria, but later it
was found to be a broad-spectrum antimalarial drug useful for
both prophylaxis in nonimmune travelers and treatment of
established infections with multidrug-resistant P. falciparum.44
Still, though tafenoquine has a longer half-life in vivo than PQ,
it seems to equally cause hematological disorders, so its use in
certain patients will possibly be blocked or limited.45
Another encouraging antimalarial 8-AQ, presently in
preclinical development sponsored by the Medicines for
Malaria Venture, is NPC-1161B (22, also referred to as
DNS-21-1; Figure 9), which shows a clear-cut enantioselective
pharmacological profile and promising antimalarial efficacy for
both clinical and radical cure.43,46 Tafenoquine and NPC-
1161B exhibited IC50 values in the 500-nM and 50-nM range
against P. falciparum drug-sensitive (NF54) and drug-resistant
(7G8) strains, respectively, and were more potent than PQ and
elubaquine (IC50 = 0.5−2.5 μM) against both strains.
47 Like
tafenoquine, NPC-1161B has an O-aryl substituent at position
5 of the quinoline ring, and both compounds seem to require
metabolic activation by CYP 2D6 as an essential factor to
Figure 7. Classical 8-aminoquinolines pentaquine (14), isopentaquine
(15) and primaquine (PQ).
Figure 8. Main metabolites of PQ: hiydroxyprimaquine (16), 6-
methoxy-8-aminoquinoline (17) and carboxyprimaquine (18).
Figure 9. PQ-based 8-aminoquinolines in clinical use in some
countries, or under clinical trials as antimalarials: quinocide (19),
bulaquine (20), tafenoquine (21) and NPC-1161B (22).
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display antimalarial activity.47 Interestingly, this finding may
provide a possible explanation for patients who do not respond
to 8-AQ like PQ for treatment of relapsing malaria, as further
discussed below.
3.3. Recycling Primaquine: Toward Novel Antimalarial
8-Aminoquinolines
In spite of the hope brought by the promising features of
tafenoquine, it is an undeniable fact that PQ remains as the
only antirelapse and transmission-blocking antimalarial in
clinical use all over the world.42,48 Furthermore, almost seven
decades have elapsed since its discovery, and no substantial and
clinically relevant resistance against PQ has been reported. Yet,
PQ has limited bioavailability and cannot be safely used in
newborns, pregnants, elderly people, or any person bearing
glucose-6-phosphate dehydrogenase (6GPD) deficiency.48,49
Moreover, vivax malaria relapses due to failure of PQ-based
therapies have been identified.50 Such failures could be
indicative of isolated cases of decreased parasite sensitivity to
the drug;51 however, they might instead be related with the
recent proposal of a relevant role of CYP 2D6 activity for PQ
antimalarial action, as PQ inefficacy has been associated with
patients with decreased CYP 2D6 activity.52 Such a finding has
been supported by recent studies with CYP 2D knockout mice
that were not cured from P. berghei infection by PQ, even when
using doses 2-fold higher than those typically efficient in wild-
type mice.53 These results have troubling implications for the
use of PQ as primary prophylaxis regimen, since, for instance,
CYP 2D6 activity is lowered in as many as 5% to 10% of
Caucasian travelers; despite the hope that genotyping and
“personalized medicine” might eliminate the risk of PQ’s lack of
efficiency in those individuals, at present CYP 2D6 testing is
neither affordable nor widely available.54 Altogether, these
aspects demonstrate the need to go on searching for
alternatives to PQ as antirelapse and transmission-blocking
antimalarial agents. Most of the PQ “chemical recycling” efforts
made throughout the second half of the 20th century have been
extensively revised elsewhere;47,55 the next examples refer to
work from 2000 on.
3.3.1. Modifications Exclusively at the Aliphatic Chain
of Primaquine. The simplest way to alter the PQ’s scaffold is
through chemical modification at the primary amine group that
terminates the drug’s aliphatic chain. Such has been majorly
addressed with the aim of producing PQ prodrugs, with the
advantage that blocking or masking PQ’s primary amine
impairs or delays drug’s inactivation by oxidative deamination
to carboxyPQ.50,56 With this goal in mind, Gomes and co-
workers have carried out the synthesis and biological evaluation
of imidazolidin-4-ones prepared from amino acid derivatives of
PQ (23, Figure 10), which exhibited potent gametocytocidal
activity in vivo against P. berghei, hence blocking transmission
from infected mice to Anopheles stephensi mosquitoes;
compounds 23 derived from small amino acids (Gly and L-
Ala) were found superior to those containing bulky/hydro-
phobic amino acid side chains (L-Phe, L-Val, and L-Leu).
Interestingly, imidazolidin-4-ones 23 were very stable at
physiological pH and T, both in aqueous buffer and in
human plasma, suggesting that they were active per se rather
than behaving as PQ prodrugs.57 In agreement with such a
hypothesis, the kinetics of hydrolysis of these PQ derivatives,
investigated at 60 °C in the pH range 0.3−13.5, was quite
different from that of imidazolidin-4-one prodrugs of peptides
(24, Figure 10).58 Additionally, compounds 23 were found to
be active against blood-stages of CQ-resistant P. falciparum
strain W2, although only at modest levels (IC50 = 2.42 to >50
μM).59
Later on, the same research group developed peptidomimetic
derivatives of PQ, with general formula 25 (imidazoquines,
Figure 10), where the imidazolidin-4-one ring was used as a
dipeptide’s proline-mimetic building block.60 The compounds
presented IC50 values ranging from 5.5 to 12 μM against the P.
falciparum W2 strain, were chemically and enzymatically stable,
and preserved the overall bioactivity pattern of PQ, including in
vivo transmission-blocking activity on the P. berghei model of
rodent malaria; yet, their activity against liver-stage malaria was
not superior to that of the parent drug.60 Remarkably,
compounds 26, isomers of imidazoquines 25 developed by
the same group, were found to behave as PQ prodrugs,
Figure 10. Synthetic route to peptidomimetic derivatives of primaquine (23−26). General conditions: (i) Nα-Boc-protected amino acid, peptide
coupling agent, dichloromethane, rt; (ii) neat trifluoroacetic acid, rt; (iii) R2(CO)R3, refluxing methanol over 3 Å molecular sieves.57,61
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undergoing hydrolysis to the parent dipeptide derivative of PQ
(27, Figure 11) in neutral and basic conditions.61
Motivated by the inspiring discovery of ferroquine as a
promising antimalarial candidate (section 5.1), organometallic
derivatives of PQ have also been approached by Gomes and co-
workers, who synthesized a diversified group of primaquine/
ferrocene conjugates (primacenes 28−33, Figure 12). These
compounds were tested as liver-stage, blood-stage, and
transmission-blocking antimalarial agents, which permitted
researchers to conclude that both transmission-blocking and
blood-stage activities were preserved only in primacenes
bearing a basic aliphatic amine group.62 In turn, in vitro liver-
stage activity did not require such a structural feature, and all
metallocenes tested were comparable to or better than PQ
against liver forms of P. berghei; remarkably, the replacement of
PQ’s aliphatic chain by hexylferrocene, as in compound 33, led
to a ∼45-fold higher in vitro liver stage activity than that of PQ
(IC50 = 1.25 to >10 μM against P. falciparum W2 strain).
62a
Unfortunately, such a promising result was not confirmed later
in in vivo assays.63
Moreira and co-workers have equally addressed PQ
derivatives that might prevent oxidative deamination of PQ
to the inactive metabolite carboxy-PQ; to this end, those
authors prepared O-alkyl and O-aryl carbamate derivatives of
PQ (34, Figure 13) as potential PQ prodrugs, and studied their
degradation kinetics; results obtained were compatible with two
alternative pathways: one where compounds 34 undergo direct
hydroxide attack at the carbonyl carbon (path A, Figure 13) to
produce carbamate 37, which then readily decarboxylates to
PQ; alternatively, the conjugate base of 34 (35, Figure 13) can
suffer E1cB elimination (path B, Figure 13) to an isocyanate
(36) that rapidly reacts with hydroxide to equally produce 37
followed by decarboxylation to PQ. Carbamates 34 were tested
in vivo for their gametocytocidal activity on P. berghei, and the
ethyl and n-hexyl derivatives were the most active, and
proposed as transmission-blocking leads.64
Somewhat similar structures have been very recently
reported by Zorc and co-workers, who synthesized 1-acyl-4-
substituted semicarbazide derivatives of PQ (38, Figure 14);
however, only the compounds’ antioxidant, cytotoxic, and
antiviral activities were described, and nothing has been yet
reported regarding their activity as antimalarials.65
Modification of the PQ’s primary amine to produce prodrugs
has also been addressed through more “exotic” approaches,
such as conjugation with sugars (39, Figure 15) and amino
acid-based polymers (40 and 41, Figure 15).66 In 2009, Rajic ́ et
al. prepared glucosamine/PQ and polyaspartamide/PQ con-
jugates as potentially useful antimalarial PQ prodrugs of
increased solubility and prolonged activity; preliminary results
showed in vivo activity of the polyaspartamide conjugates
against P. berghei infection in mice, but the potential of these
conjugates on pre-erythrocytic stages of parasitemia or as
transmission blocking agents was not reported.66a Similarly,
Tomiya et al. have very recently reported the development of
PQ/polymer conjugates (41, Figure 15), in this case designed
to target liver cells; such conjugates were based on poly-L-
glutamic acid modified with a glycosidic ligand specific to the
hepatocyte asialoglycoprotein receptor, and were found to
target and internalize rat hepatocytes, there being extensively
Figure 11. Kinetics of hydrolysis of imidazolidin-4-ones 26 at 37.0 °C
originating the dipeptide derivatives of PQ (27).61
Figure 12. Organometallic derivatives of primaquine (28−33)
developed by Gomes and co-workers.62
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degraded; however, the antimalarial activity of such conjugates
was not yet reported.66b
3.3.2. Modifications Involving the Quinoline Ring in
Primaquine. The fact that major PQ’s toxic metabolites arise
from modifications in certain positions of the quinoline ring has
motivated an intense search for PQ surrogates where such
positions were blocked by suitable substituents. Hundreds of 8-
AQ were thus generated and evaluated in the last quarter of the
20th century, with some positive results that have been
conveniently revised elsewhere, and of which tafenoquine is the
most prominent example.42,48,67 Recent efforts have almost
invariably included chemical modifications at both the
quinoline ring and the aliphatic chain. For instance, Jain and
co-workers have developed compounds 42 (Figure 16), with
interesting blood-schizontocidal activities in vivo against P.
berghei (drug-sensitive strain) and P. yoellii nigeriensis (highly
virulent multidrug-resistant strain) in mice; compound 42d was
curative at 5 mg/kg on P. berghei malaria, whereas 42e exhibited
curative activity at 50 mg/kg against P. yoellii nigeriensis.68
However, neither blood-stage inhibition of P. falciparum nor,
more relevantly, liver-stage activity of these PQ surrogates was
reported.
The same research group also found that placement of a
metabolically stable tert-butyl group at the quinolinic C-2 of PQ
to produce 2-tert-butyl-PQ (43, Figure 16) results not only in a
tremendous enhancement of blood-stage antimalarial activity
(IC50 = 39.06 ng/mL against P. falciparum W2 strain) but also
in significant decrease of hematotoxicity.69 Such a finding was
interpreted as possibly arising from a disturbance of the heme
catabolism pathway in the malarial parasite.70
The same authors also reported bis(8-aminoquinolines) 44
(Figure 17) with promising antimalarial activity in vitro against
drug-sensitive (D6, IC50 = 1.6−4.76 μg/mL) and drug-resistant
(W2, IC50 = 0.3−3.6 μg/mL) strains of P. falciparum, and
potent in vivo activity in the rodent model of malarial
infection.71 The compounds had also decreased hematotoxicity,
as compared to PQ, and moderately inhibited β-hematin
formation, suggesting this as a plausible pathway of their
antimalarial activity.71 Following these discoveries, the same
group reported the design, synthesis, and evaluation of three
new series of PQ-based 8-AQ modified at the terminal primary
amine (45, Figure 17).72 The presence of carboxyl groups
seemed disadvantageous, as compounds from series 1 (IC50 =
4.76 and 4.2 μg/mL) were less potent than PQ (IC50 = 2.8 and
2.0 μg/mL) against P. falciparum W2 and D6 strains,
respectively. However, the presence of basic amino acids L-
Arg and L-Lys, as in series 2 (IC50 = 0.4−4.76 and 2.0−4.76 μg/
mL) and 3 (IC50 = 0.26−4.2 and 0.13−3.8 μg/mL), led to
encouraging in vitro results, again including decreased
hematotoxicity as compared to PQ. Additionally, when tested
for their in vivo blood-schizontocidal activity against P. berghei
infected mice, compounds from series 2 and 3 containing the L-
Lys amino acid as substituent exhibited 100% curative activity
at an oral daily dose of 100 mg/kg for 4 days.72 However, the
analogue from series 3 displayed a lower selectivity index (SI)
(SI > 8.5; SI = IC50 VERO/IC50 Pf W2) compared to its series
2 analogue (SI > 91.5).
The same authors have also studied extended side chain
analogues of PQ (46, Figure 18) that exhibited potent
antimalarial activities in vitro against both drug-sensitive D6
(IC50 = 0.19−2.6 μg/mL; SI > 9.1 to >125) and drug-resistant
W2 (IC50 = 0.12−1.5 μg/mL; SI > 15.8 to >198) P. falciparum
strains. The most promising compounds were proven to be
100% curative in vivo on P. berghei-infected mice after a 4-day
treatment (25 mg/kg daily dose). These analogues were also
found not to be cytotoxic up to 23.8 μg/mL and to inhibit β-
hematin formation (IC50 = 9.6−20.8 μM) in vitro, underlining
the disruption of heme catabolism by the malaria parasite as the
potential biochemical pathway for their antimalarial action.73
Overall, reports on 8-AQ, such as compounds 42−46, that
are devoid of significant hemotoxicity and display appreciable
blood-stage activity, emerged as a breakthrough. Should the
efficacy of such compounds against liver and sexual
(gametocytes) forms of Plasmodia been proven, the consequent
discovery of triple-action PQ surrogates safe for use by 6GPD-
deficient patients would have represented a new era in
antimalarial chemotherapy. Unfortunately, to the best of our
knowledge, neither the liver-stage or gametocytocidal activity of
42−46 has been reported up to today, nor have any of these
compounds yet stepped forward into clinical development.
Other PQ alternates have been obtained by changes in the
quinoline core structure itself, such as those reported by Zhu et
al., who replaced the quinoline ring by a 1,5-naphthyridine (47,
Figure 19). The resulting compounds displayed IC50 values
ranging from 0.021 to 0.11 μM against P. falciparum W2 strain
and excellent in vivo blood-schizontocidal activity against both
P. berghei (ED50 = 0.26−1.8 mg/kg) and P. yoelii nigeriensis
(ED50 = 0.23−2.1 mg/kg), while being over three times less
toxic than PQ. In that work, the authors further found that
introducing a substituent at position 2 (R1 in 47) reduced
toxicity, while preserving the desired antimalarial activity; in
turn, variation of substituent groups at the naphthyridine’s
position 6 did not have a significant effect in the compounds’
Figure 13. Degradation pathways of 34 to release parent drug PQ,
according to Moreira and co-workers.64
Figure 14. New PQ-semicarbazide derivatives 38 from Zorc’s group.65
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toxicity.74 Regrettably, this report also lacked information
regarding the compounds’ activity against liver and sexual forms
of Plasmodia, an assessment that should be regarded as
mandatory when seeking for worthy PQ substitutes.
3.3.3. Dual-Core Hybrids. The previous subsections
clearly demonstrate that finding a suitable PQ surrogate to
enter the clinics is revealing itself to be a quite difficult
endeavor. Although derivatives with enhanced blood-stage
activity and reduced toxicity have been successfully developed
in the late few years, their performance as tissue-schozontoci-
dals (i.e., active against liver-stage parasites) and transmission-
blockers was not reported or did not supersede that of PQ
itself. This is a major drawback in current antimalarial
chemotherapy, as it is now well-established that malaria
eradication will possibly become more than a mirage only
when efficient elimination of liver-stage Plasmodia and blocking
of host-vector transmission are achieved. Quoting 2011’s
malERAa research agenda for malaria eradication“drugs
will continue to be used to treat acute malaria illness and
prevent complications in vulnerable groups, but better drugs
are needed for elimination-specific indications, such as mass
treatment, curing asymptomatic infections, curing relapsing
liver stages, and preventing transmission”.75
In view of the above, some authors have been using the
double-drug approach, by synthesizing molecular constructs
where PQ is covalently bound to other building blocks
[potentially] exhibiting complementary antimalarial properties.
In this connection, the most obvious approach is combination
of PQ with other well-known antimalarial pharmacophores,
such as the artemisinin or the chloroquine cores. Accordingly,
Moreira and co-workers developed two dual-core hybrids
where PQ was covalently linked to artemisinin-based moieties
(48, Figure 20), and they found them to display enhanced in
vitro activities against liver-stage P. berghei, as compared to both
parent drugs. Moreover, both molecular constructs were about
as potent as ART against cultured P. falciparum W2 strain (IC50
Figure 15. PQ conjugates (39−41) with sugars and/or amino acid-based polymers.
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= 12.5 and 9.1 nM for 48a and 48b, respectively), and one of
the compounds (48a) performed better in vivo against murine
P. berghei infection than an equimolar mixture of the parent
pharmacophores.76 Unfortunately, additional preclinical studies
on these rather promising hybrids have not been reported up to
today.
Subsequent approaches to antimalarial hybrids encompassing
the PQ core have addressed its conjugation with motifs
potentially able to inhibit proteases of chief importance for
intraerythrocytic parasites. For instance, Romeo et al. have
coupled PQ to statine-based inhibitors of plasmepsin II
(PLMII) (49, Figure 21), as statins are known to inhibit
plasmepsins, aspartic proteases that are crucial for the
development of blood-stage Plasmodia; hybrids 49 were
found to exhibit IC50 values for PLMII inhibition ranging
from 0.59 to 400 nM. The IC50 range for inhibition of P.
falciparum D10 and W2 growth in vitro was 0.4−5.5 and 0.7−
4.7 μM. Although these results are not exciting, they represent a
remarkable improvement over other statine-based PLMII
Figure 16. Amino acid derivatives of 4-mono- and 4,5-disubstituted-
PQ (42), and structure of 2-tert-butylPQ (43) developed by Jain et
al.68,69
Figure 17. PQ-based 8-AQ (44−45) developed by Jain and co-
workers.71,72
Figure 18. Structures of double, triple and quadruple extended side chain analogues (46) of PQ-based compounds developed by Jain and co-
workers.73
Figure 19. Naphthyridine analogues of PQ (47) developed by Zhu et
al.74
Figure 20. PQ/artemisinin hybrids (48) as a multistage antimalarial
strategy developed by Moreira and co-workers.76
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inhibitors.77 Awkwardly, neither the liver-stage nor transmission
blocking activity of these PQ-statin hybrids was reported.
Following a similar line of thought, a more recent report by
Gomes and co-workers described conjugation of PQ with
different cinnamic acids (50, Figure 22), eventually capable of
irreversibly inhibiting falcipains, P. falciparum cysteine proteases
relevant for the parasites’ blood-stage development; the hybrids
were designed on the grounds that (i) cinnamic acid derivatives
had been reported as displaying interesting antimalarial
properties and (ii) the α,β-vinylcarbonyl moiety of the
cinnamoyl group might participate in a Michael-type addition
involving the enzyme’s catalytic cysteine thiol (Scheme 1).
These hybrids displayed increased in vitro activity against liver-
stage P. berghei parasites (IC50 = 1.38−2.39 μM), as compared
to the parent PQ, and they were nontoxic to human hepatoma
cells. However, they were both devoid of significant blood-stage
activity (IC50 > 4.84 mM against P. falciparum W2 strain) and
unable to inhibit falcipains in vitro.78
Surprisingly, conjugation of the 20th century antimalarial
stars PQ and CQ into a single hybrid drug (51, Figure 23) was
only very recently addressed by Lödige and co-workers. These
authors found that such a PQ/CQ hybrid did not significantly
affect sporozoites’ motility or ability to invade hepatocytes in
vitro but was able to perturb development of liver-stage P.
berghei and of both asexual and sexual (gametocytes) blood-
stage P. falciparum (IC50 = 0.64, 0.58, and 0.08 μM against P.
falciparum 3D7, Dd2, and K1 strains, respectively). Interest-
ingly, though the in vitro performance of hybrid 51 was overall
moderate, and generally lower than that of the equimolar
mixture of its parent drugs, it performed better than CQ alone
or its 1:1 mixture with PQ against the CQ-resistant P.
falciparum K1 strain. More relevant still, hybrid 51 was active in
vivo against both liver-stage parasitemia and blood-stage
infection, while also being able to prevent blood stage potency
and to treat the symptoms of experimental cerebral malaria.79 It
is thoughtful that such a promising lead is now emerging from
the recycling of two top antimalarial drugs of the past century.
4. ANTIMALARIAL ACRIDINES: REVIVAL OF
QUINACRINE, THE FIRST SYNTHETIC
BLOOD-STAGE ANTIMALARIAL
Acridine (AC, Figure 24) is a relevant pharmacophore in, e.g.,
antimalarial, antimicrobial, antitumoral, antiprionic, anti-Alz-
heimer, and antileishmanial agents.80 The most consensual
mechanism of action (MOA) of AC derivatives against different
diseases is interaction with DNA.81 However, other MOA have
been evoked to explain the antimalarial activity of AC
derivatives, such as inhibition of parasite’s (i) mitochondrial
bc1 complex, (ii) type II topoisomerases, (iii) hemozoin
formation, or even chemosensitization. The latter refers to
the effect of some compounds, or compound moieties, in
reversing Plasmodium resistance to classical antimalarial drugs
such as chloroquine (CQ, Figure 6).80f
The interest in AC-based structures as antimalarials also
emerged from early discoveries on antimicrobial/antiprotozoan
activity of the classic synthetic dyes MB (Figure 6, as
mentioned on section 2) and, later, acridine orange (ACO,
Figure 24), whose activity against P. falciparum 3D7 (IC50 = 7.8
and 465.7 for MB and ACO, respectively) and Dd2 strains
(IC50 = 14.3 and 166.0 nM for MB and ACO, respectively) has
been recently re-evaluated.82 Both the toxicity and tendency to
induce skin coloration of MB soon motivated the search for
more adequate antimalarial surrogates, which led to the
synthesis of quinacrine (QN, Figure 6), in 1932.83 QN was
widely used as an antimalarial by soldiers during WWII (Pacific
Figure 21. PQ/statin hybrids (49) developed by Romeo et al.77
Figure 22. PQ/cinnamic acid conjugates (50) reported by Gomes and
co-workers.78
Scheme 1. Michael-Type Addition Involving an Enzyme’s
Catalytic Cysteine Thiol
Figure 23. PQ/CQ hybrid (51) developed by Lödige et al.79
Figure 24. Structures of acridine (AC) and acridine orange (ACO).
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War) but was soon superseded by CQ, whose efficiency,
bioavailability, and safety were considerably superior.80e,84
When widespread resistance of P. falciparum to CQ became
indisputable, by the late 1960s, the search for more efficient
QN derivatives or analogues regained stamina. Such led to the
synthesis, in the 1970s, of pyronaridine (PYR, Figure 25), an
anilinoacridine topoisomerase II inhibitor, active in vitro and in
vivo against drug-resistant P. falciparum strains; although this
QN-based antimalarial has been in clinical use in China since
the 1980s, parasite resistance and embryotoxicity issues have
prevented its use as monotherapy elsewhere.85 Still, good
results from clinical trials using a PYR + artesunate
combination in adults led to approval of such a combination
(marketed as Pyramax) by the WHO and the European
Medicines Agency (EMA) in 2012, for use as a single treatment
course against acute, uncomplicated P. falciparum or P. vivax
malaria infection in adults and children above 20 kg, in areas of
low transmission with evidence of ART resistance.86
4.1. Acridine-Inspired Antimalarial Leads: Acridones and
Related Structures
The lack of information on PYR’s safety regarding (i) children
below 20 kg or under 12 years old, (ii) adults over 65 years old,
(iii) impairment of renal and hepatic function, and (iv)
repeated treatment courses underpinned the continuous effort
toward development of novel acridine-inspired antimalarials. In
1994, the WRAIR proposed floxacrine (52, Figure 26), an
antimalarial dihydroacridinedione.86a,87 However, daily dosages
between 1.25 and 2.5 mg/kg were needed for transient
clearance of parasitemia, and Plasmodia quickly became
resistant to this drug.88 Moreover, floxacrine displayed
suboptimal solubility and was soon associated with chronic
periarteritis in animals, which led Raether et al. to investigate
new floxacrine derivatives, where four (53−56, Figure 26; IC50
= 0.73−96 nmol against P. falciparum FCBR strain) were
selected out of nearly two hundred produced. Unfortunately, in
vitro and in vivo assays on the blood schizontocidal activity of
such compounds on different drug-resistant strains of P. berghei
and CQ-resistant P. falciparum showed that the limitations
posed by floxacrine had not been overcome.89
In an effort to recycle the floxacrine scaffold toward new
antimalarial structures, WRAIR later developed another
dihydroacridinedione, WR243251 (57, Figure 27), having
high blood-schizontocidal activity in vitro against a meflo-
quine-resistant, CQ-sensitive strain (D6; IC50 = 11 nM), a CQ-
susceptible strain (NF54; 4.4 nM), and a CQ- and pyrimeth-
amine-resistant strain (W2; IC50 = 25 nM).
87,90 Preclinical in
vivo assays with this compound showed it to be 100% curative
in mice at a dosage of only 12−20 mg/kg, comparably lower
than those for antimalarials in the clinical setting by then.
WR243251 was equipotent to CQ in inhibiting hemozoin
formation in vitro, and its hydrolysis resulted in a ketone
product, WR243246 (58, Figure 27; IC50 = 6.1 nM against P.
falciparum NF54 strain), whose S-enantiomer (WR249685)
also displayed potent in vitro antimalarial activity (IC50 = 15 nM
against P. falciparum 3D7 strain) but was unable to inhibit
hemozoin formation.87,90
Additional computational and experimental studies on these
compounds showed their main MOA to be inhibition of the
parasite’s cytochrome bc1 complex involving interference with
the quinol oxidation site (Qo).
90 This was a relevant finding, as
atovaquone (59, Figure 28) is the only bc1 complex inhibitor in
the current antimalarial clinical setting, against which parasite
resistance has been identified; relevantly, atovaquone-resistant
Plasmodia did not present cross-resistance to acridinediones,
Figure 25. Structure of pyronaridine (PYR).
Figure 26. Floxacrine and derivatives studied by Raether et al.87,89
Figure 27. Structures of antimalarial dihydroacridinedione derivatives
(WR243251, 57 and WR243246, 58) developed by WRAIR.87,90
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which turns the latter interesting leads into a new generation of
antimalarials acting through interference of the plasmodial
electron transport chain.91 Moreover, a bc1 complex inhibitor,
decoquinate, was recently found as a potent multistage
antimalarial compound, emphasizing the relevance of including
this MOA in future medicines for malaria eradication.92 Still,
despite all the promising features of WR243251, adverse
dermatologic, cardiovascular, and neuropsychiatric effects have
possibly prevented its clinical development.87
Altogether, findings such as those above-described have been
fueling research on other floxacrine-based structures as
potential antimalarials. Recently, Cross et al. produced a series
of acridone analogues of floxacrine (Figure 29) and tested their
solubility, antimalarial activity, and permeability. The main
structure−activity relationships (SAR) drawn by these authors
allowed concluding that acridones with aryl substituents in
positions 6 and 7 presented optimal antimalarial activity (IC50 =
12.2−58.2 nM against P. falciparum W2 strain) and
physicochemical properties.93
Other acridones have been explored as potential antima-
larials, many of which were inspired by known antimalarial
xanthones. Ignatushchenko et al., when trying to understand
both MOA and SAR of hydroxyxanthones, found that xanthone
(60, Figure 30) significantly inhibited hemozoin formation.94
Subsequently, Kelly et al. gathered xanthones’ heme-binding
ability with the relevance of protonable amines in positions 3 or
6 of the xanthone ring to design compounds 61a and 61b
(Figure 30); the latter presented IC50 values of 0.10 μM and
0.07 μM, respectively, against P. falciparum strain D6, being
1000-fold more active than dihydroxyxanthone (62, IC50 > 60
μM).95 Based on this knowledge, Winter et al. pursued novel
acridone derivatives which might enrol the ability to inhibit
hemozoin formation with chemosensitizing properties. To this
end, those authors started by synthesizing and evaluating 30
new derivatives of 2-methoxy-6-chloroacridone in order to
build some SAR. Haloalkoxyacridones presented potent activity
against P. falciparum in vitro, with the best compound (63,
Figure 30) exhibiting an extraordinary picomolar IC50 value (1
pM against P. falciparum D6 strain) and a low level of
cytotoxicity (IC50 > 25000 nM against murine splenic
lymphocytes); this compound presented a bis(trifluoromethyl)-
fluoroalkoxy group, somewhat evoking the trifluoromethyl
substituent in floxacrine.96 Later on, the same researchers
synthesized acridone derivatives with N-alkylamine substituents
in position 10 (64, Figure 30; IC50 = 2.6−11.8 and 1.6−10.2
μM against P. falciparum D6 and Dd2 strains, respectively), and
they found them to display the desired chemosensitization
properties and synergy with CQ against CQ-resistant P.
falciparum.97 Further results demonstrated that linking an
ionizable side chain to position 6 of the 10-N-substituted
acridones (65, Figure 30; IC50 = 44.8 and 77.3 nM against P.
falciparum D6 and Dd2 strains, respectively) promotes
compound’s accumulation in the parasite’s food vacuole (FV)
and interferes with hemozoin formation; moreover, compound
65 showed synergy with quinine, since only one-third of the
individual dosage was needed to have the same effect as when
given separately.98
A similar set of acridones, bearing different 10-N-
substitutions (allyl, 3-methyl-2-buthenyl, and 1,2-propadienyl)
and a chlorine or fluorine atom in positions 1, 2, or 6 of the
acridone moiety, was also synthesized and evaluated by
Fernandez-Calienes et al. Though the best compound (66,
Figure 31) was a hit, as it exhibited an IC50 (0.16 μg/mL
against P. falciparum GHA strain) below the 0.2 μg/mL
threshold to qualify as such and presented a SI of 112.2 (SI =
Figure 28. Structure of atovaquone (59).
Figure 29. Structure activity relationship of compounds studied by
Cross et al.93
Figure 30. Antimalarial xanthones (60−62) and acridones (63−65)
developed by Winter and co-workers.94−98
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IC50 MRC-5/IC50 Pf GHA), its antimalarial activity was low
when compared with acridone 65.99 Furthermore, 66 could not
inhibit hemozoin formation; instead, it inhibited the bc1
complex, still not with the same specificity as the aforemen-
tioned acridinediones developed in the WRAIR.90b,99
4.2. Revival of Quinacrine and Pyronaridine: In Pursuit of
Next Generation Antimalarial Amino- and
Aniline-Acridines
4.2.1. 9-Aminoacridine Leads. Fair efforts have been
done during the first eighth of this century toward rejuvenation
of QN-inspired antimalarials. In 2001, Chibale and co-workers
developed a series of compounds where the acridine core of
QN has been linked to a second aromatic moiety through
sulfonamide (67, Scheme 2) or urea groups (68, Scheme 2), in
order to improve compounds’ solubility. The synthetic route
employed (Scheme 2) required preactivation of the starting 9-
chloroacridine with phenol, to produce a reactive 9-
phenoxyacridine intermediate, followed by nucleophilic ar-
omatic substitution with a diamine to yield the desired 9-(N-
aminoalkyl)aminoacridine; this was then reacted with either
naphthylsulfonyl chloride or benzyl isocyanate, to give final
products 67 and 68, respectively. Ureas 68 had the highest
antimalarial activities (0.0005 < IC50 < 0.069 μg/mL) against P.
falciparum 3D7, some of them being more potent than
reference CQ (IC50 = 0.002 μg/mL). However, cross-resistance
with CQ may be a feature of these compounds, as 68 was more
active against P. falciparum CQ-sensitive strain 3D7 (IC50 =
0.0005 μg/mL) than against the CQ-resistant strain K1 (IC50 =
0.015 μg/mL). Moreover, compound 68 was found to be toxic
against human KB cells.100
More conservative approaches to structural variation around
QN have also been reported. Anderson et al. produced
compounds 69−74 (Figure 32), which translate globally into
simple modifications of the original QN scaffold. The
compounds presented potent in vitro activity against P.
falciparum 3D7 (1.0 < IC50 < 4.1 nM) and W2 (1.0 < IC50 <
7.6 nM), and two of them (69 and 72) actually exhibited
subnanomolar activity against 3D7. Overall, all compounds
performed better than QN (IC50 = 8.1 nM and IC50 = 32.1
nM) and CQ (IC50 = 7.0 nM and IC50 = 382.2 nM).
Interestingly, results from this work generally suggested some
flexibility in modifications at the QN’s side chain, as both furyl
(71 and 74) and alkyl groups (72 and 73) were well tolerated.
Still, the two best compounds were those whose structure most
resembled that of parent QN, i.e., compounds 69 and 72.101
Despite the promising features of the QN derivatives above,
to the best of our knowledge, they were not taken further to
clinical development. A possible reason for that may have been
related with purity requirements, as the authors mention some
difficulty in obtaining good purity degrees due to a persistent
acridone impurity.101
Parallel efforts by Guetzoyan et al. were built on the
knowledge that optimal antimalarial activity was obtained when
(a) the 9-aminoacridine core is 6-chloro-2-methoxy-substituted
(as in QN) and (b) at least two protonable groups, one in the
acridine core and the other in the aliphatic side chain, are
present. Hence, these authors prepared QN analogues where
arginine-N-terminated oligopeptides were coupled to the
primary amine of the aliphatic side chain (Figure 33). These
peptidyl derivatives were evaluated in vitro against P. falciparum
3D7 and found to display only modest micromolar-range
activities (IC50 = 0.13−42 μM).
102 In view of this, the same
authors removed the oligopeptide motif to produce compounds
75 (Figure 33), but the best compound (75a) was still less
active (IC50 = 0.042 μM; SI = 50) than CQ (IC50 = 0.018 μM)
against P. falciparum 3D7.103
Modification of the QN’s aliphatic chain by terminal
insertion of heterocyclic motifs has also been approached.
Sparatore et al. produced QN analogues (76, Figure 34)
through introduction of a quinolizidinylalkyl moiety in the
amino group of the 9-amino-6-chloro-2-methoxyacridine core,
aiming at improving the drug’s bioavailability and pharmaco-
kinetics; these analogues displayed in vitro activities against CQ-
resistant (W2) and CQ-sensitive (D10) P. falciparum in the
midnanomolar range (IC50 = 68−97 and 31−43 nM,
respectively), but they were found to be as toxic as QN and,
consequently, more toxic than reference drug CQ.104 Following
a similar line of work, Yu et al. have recently introduced
piperazinyl, pyrrolidinyl, imidazolyl, or morpholinyl rings in the
side chain of QN (Figure 34), as these motifs have been
associated with increased bioavailability, metabolic stability, and
tolerability in humans. The best compounds were the
morpholinyl derivatives (77, Figure 34), which displayed (i)
moderate capacity to inhibit hemozoin formation, (ii) activity
against both CQ-resistant (IC50 = 30 nM; SI = 3.7−7.2) and
CQ-sensitive (IC50 = 9−10 nM; SI = 12.2−21.5) P. falciparum
strains similar to that of parent QN, (iii) moderate cytotoxicity,
and (iv) potent activity on topoisomerase VI-mediated DNA
relaxation.105 This last aspect may be relevant to confer
Figure 31. Best antimalarial acridone reported by Fernandez-Calienes
et al.99
Scheme 2. Synthetic Route toward Chibale’s Sulfonamide
(67) and Urea Derivatives (68) of QN100
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selectivity to antimalarial compounds such as 70, as
topoisomerase VI is a unique type of the topoisomerase II
family that is almost absent in eukaryotes.106 According to the
authors, most potent compounds would step forward to in vivo
evaluation on model malaria infection, using P. berghei infected
mice. To the best of our knowledge, data from such in vivo
assays has not been published yet.
4.2.2. 9-Anilinoacridine Leads. Structural variations
around the 9-anilinoacridine core of PYR have also been
analyzed over the past few years, based on research conducted
in the 1990s, such as that from Figgitt et al. These authors had
screened antitumoral anilinoacridine analogues of PYR against
malaria, observing submicromolar activity (IC50 = 0.1 μM)
against P. falciparum for structures presenting amine groups at
positions 6 and 1′ of the acridine and aniline rings, respectively
(78, Figure 35).107 The same authors later introduced an
additional amino group in position 3 of the acridine ring to
yield 78a, with a concomitant four times increase in the
antimalarial activity (IC50 = 0.025 μM).
108 Motivated by these
findings, Auparakkitanon et al. have studied the effect of
different substitutions at both the aniline and acridine moieties
of PYR (Figure 35) on their ability to block hemozoin
formation and inhibit type II topoisomerases in P. falciparum;
results showed that structures with a 3,6-diamino-substituted
acridine core (79, Figure 35) were superior to their 3,6-dichloro
counterparts in vitro against Plasmodia, with the best of which
(79a) displaying nanomolar activity (IC50 = 34 nM) against P.
falciparum K1.109 The compounds were able to inhibit both
Figure 32. QN analogues (69−74) developed by Anderson et al.101
Figure 33. Compounds developed by Guetzoyan et al.103
Figure 34. Heterocyclic derivatives of the QN’s 9-amino-7-chloro-2-
methoxyacridine core of QN developed by Sparatore et al. (76) and
Yu et al. (77).104−106
Figure 35. Anilinoacridine derivatives developed by Figgit et al. (78)
and Auparakkitanon et al. (79).107−110
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topoisomerase II activity and hemozoin formation, but 79a was
later found not to efficiently penetrate the parasite’s FV, thus
presenting weak interaction with intracellular hematin.110
Addition of a third cyclic motif to 9-anilinoacridines has also
been approached. Following earlier work where use of triazine
moieties was found beneficial for antimalarial activity,111 Kumar
and co-workers synthesized 9-anilinoacridine triazine deriva-
tives (80a−c, Figure 36) that were shown to be almost twice as
potent in vitro (IC50 = 4.21−6.97 nM; SI = 295.02−2896.02) as
CQ (IC50 = 8.15 nM; SI = 8983) against P. falciparum 3D7
strain.111,112 The best compounds were tested in vivo against
CQ-resistant P. yoelii N-67 infection in mice, but despite being
orally active and leading to a suppression >95% at day 4 post-
treatment (daily dose of 100 mg/kg), the compounds were
unable to provide protection in a 28 day survival assay.112 Later,
Tomar et al. inserted a p-cinnamoyl substituent in the 9-anilino
moiety of PYR, thus producing 9-aminochalcone-acridines such
as 81a (Figure 36). These compounds potently inhibited
parasite maturation at concentrations below 10 μg/mL, and
groups at the 4′ position of the cinnamoyl ring were found as
crucial to such antimalarial activity: the p-methoxy-substituted
structure 81a (Figure 36) was the best, leading to 71.4%
inhibition at 2 μg/mL.113 Prajapati et al. proposed similar
chalcone derivatives such as 81b, which simply resulted from
replacement of the acridine core in 81a by its 6-chloro-2-
methoxy-substituted congener (Figure 36). Antimalarial
activities in vitro ranged from IC50 = 0.30 to 4.8 μM against
P. falciparum 3D7 (SI = 13.5−333) and from IC50 = 0.15 to 4.5
μM against P. falciparum Dd2 (SI = 10−520), still below those
of reference CQ against both strains (IC50 = 0.04 μM and 0.17
μM, respectively). Interestingly, the best compound also
displayed a p-methoxy-substituted cinnamoyl ring.114
4.2.3. Organometallic Leads. The success of the
antimalarial drug candidate ferroquine (see section 5.1)
prompted the search for organometallic leads derived from
other classical antimalarials, such as QN.115 In this connection,
Blackie et al. produced a ferrocene derivative of QN (82, Figure
37) that presented the remarkable IC50 values of 1 nM and 8
nM against 3D7 and K1 P. falciparum strains, respectively.
These activities were higher than those exhibited by ferroquine
itself in vitro, a fact that the authors considered as possibly due
to simultaneous exertion of different antiplasmodial MOA by
compound 82. Unfortunately, further studies have suggested
that undesired toxicity effects might be associated with the
ferrocenyl moiety.116
A cobalt-based organometallic derivative of QN (83, Figure
38) has also been developed by Ajibade et al., who found it to
be more potent (IC50 = 0.02 μM) than the same complex with
CQ (IC50 = 4.41 μM) against P. falciparum K1.
117 Additionally,
83 was also found to be the least cytotoxic (CC50 = 7.26 μM)
from a total of five cobalt complexes synthesized by Ajibade and
co-workers.
Most recent organometallic derivatives of QN have been
inspired in antitumoral cisplatins. The fact that 9-amino-
acridines such as QN interact with DNA and present
interesting antiproliferative activities underlies their relevance
against malaria as well, since maturation of intraerythrocytic
parasites equally relies on fast DNA replication.118 In view of
this, Murray et al. have hypothesized that conjunction of the
acridine core with a cisplatin moiety, as in 84a,b (Figure 39),
would probably yield valuable antimalarial hits; such com-
pounds were actually active in vitro as antimalarials (IC50 =
0.18−0.34 μM) but did not reach nanomolar activities against
the P. falciparum FCQ-27 strain.119
Figure 36. PYR derivatives obtained by insertion of a third cyclic
building block, as proposed by Kumar et al. (80a−c), Tomar et al.
(81a) and Prajapati et al. (81b).112−114
Figure 37. Organometallic surrogate of QN (82) developed by Blackie
et al.116
Figure 38. Cobalt QN derivative (83) developed by Ajibade and co-
workers.117
Figure 39. Cisplatin QN derivatives (84) developed by Murray et
al.119
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4.2.4. Quinacrine Hybrids. Inspired by recent trends with
a focus on hybrid drugs, obtained by covalently binding two or
more pharmacophores in a single molecular construct, Girault
et al. produced bis(9-amino-6-chloro-2-methoxyacridines) by
linking two acridine cores to each other through different
spacers (alkanediamines, linear polyamines, or branched
polyamines); one such dual-core compound (85, Figure 40)
exhibited potent activity against P. falciparum strain FcB1R
(IC50 = 17 nM) and was nontoxic to MRC-5 cells.
25,120 Based
on this finding, Kumar et al. later developed a series of
quinoline/acridine hybrids also using different linkers between
those two cores (86−88, Figure 40); the compounds were
confirmed to be active in vitro against P. falciparum strain NF54,
and the authors observed that the activity was increased when
replacing the p-phenylenediamine linker in 87 (MIC = 0.5 μg/
mL) by its m-phenylenediamine isomer in 88 (MIC = 0.25 μg/
mL).121 Although promising, none of the compounds (0.25 <
MIC < 1 μg/mL) performed better than the reference CQ
(MIC = 0.125 μg/mL).
The relevance of artemisinin-based antimalarials in the
current clinical strategies against CQ-resistant malaria also led
to exploration of several endoperoxides, and derived hybrid
constructs, as potential antimalarial leads. Based on the
antimalarial activity of CQ/trioxolane hybrids against sensitive
and resistant P. falciparum, reported by Cosled́an et al.,122
O’Neill and co-workers developed hybrid constructs joining the
QN acridine core with either the artemisinin’s endoperoxide
core (89, Figure 41) or a trioxolane motif (90, Figure
41).122,123 The compounds were evaluated against P. falciparum
CQ-sensitive (3D7; IC50 = 12.32−16.34 and 9.67−12.52 nM
for compounds 89 and 90, respectively) and CQ-resistant (K1;
IC50 = 14.34−20.22 and 6.76−11.10 nM for compounds 89
and 90, respectively) strains and were found to display
nanomolar activities against both strains, hence presenting no
cross-resistance with CQ.123 Many of these hybrids were
actually more active than artemisinin, and easily transformed
into water-soluble salts, making them suitable for oral and
intravenous administration. However, none of them was
superior to artemether, suggesting that their expectedly
enhanced accumulation within the parasite’s FV was not
happening and that they might have other targets outside the
FV. Finally, the authors used a model trioxolane (Scheme 3) to
demonstrate that hybrids 90 could be activated within the
ferrous-rich FV to release a QN-cyclohexanone structure
through a Fe(II)-mediated degradation pathway. Such would
mean that the hybrids enclose the ability to be active per se and
also through release of a hematin-binding antimalarial
moiety.123 Still, despite the fact that a similar quinoline/
trioxane hybrid has been selected for development as drug
candidate, as far as we know, none of the QN/trioxane hybrids
has reached that far up to date.122
Later, based on promising findings on CQ/cinnamic acid
conjugates as dual-stage antimalarials (see section 5.2.3),
Gomes and co-workers developed new hybrids through
combination of the acridine core with a cinnamoyl moiety
(91, Figure 42). These hybrids were active against both blood-
and liver-stage parasites, and were generally less toxic to human
Figure 40. Dual-core bis-acridine and quinoline/acridine hybrids
respectively developed by Girault et al. (85) and Kumar et al. (86−
88).120,121
Figure 41. QN-based hybrids developed by O’Neill and co-workers
(89 and 90).123
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hepatoma cells than QN.124 These authors confirmed that the
presence of 6-chloro and 2-methoxy substituents on the
aminoacridine core increased activity against blood-stage
parasites; for instance, the best hybrid derived from
unsubstituted 9-aminoacridine (91a, Figure 42; IC50 = 138
nM) was over three times less active than its 6-chloro-2-
methoxy-substituted congener (91b, Figure 42; IC50 = 41 nM;
SI = 428) against CQ-resistant P. falciparum W2.124 The blood-
stage activity of these QN surrogates was globally superior to
that of (i) parent QN against three tested P. falciparum strains
(CQ-sensitive 3D7, resistant Dd2 and W2), and (ii) CQ against
both CQ-resistant strains. The best compound of the series
(91c, Figure 42) was about four times more efficient against
liver forms of P. berghei (IC50 = 4.9 μM) than the reference
drug for liver-stage malaria, PQ (IC50 = 7.5 μM), and devoid of
toxicity to HepG2 cells (CC50 = 164.7 mM as compared to 7.4
μM for QN). Such findings were reported only very recently, so
additional information on in vivo performance, and other
preclinical assessments, is yet unavailable.124b
5. ANTIMALARIAL 4-AMINOQUINOLINES: KEEPING
TRACK ON 21ST CENTURY CHLOROQUINE
SURROGATES
5.1. Historical Synopsis of Clinically Relevant Antimalarial
4-Aminoquinolines
As mentioned before, one of the earliest synthetic antimalarials
to be used in the clinics was quinacrine, which constituted, ex-
aequo with quinine, first-line antimalarial therapy until 1940. As
explained in section 2.2, working from QN, Andersag
discovered CQ in 1934, originally named resochin.125 However,
initial safety studies performed in animals and humans
suggested this compound to be too toxic for clinical
development; as a result, Andersag concentrated his efforts
on the development of a methylated derivative, sontochin
(Figure 43), which seemed to present an acceptable safety
profile.125 In the early 1940s, this compound advanced to
clinical trials in Tunisia, jointly conducted by German and
French researchers.30 In 1943, French authorities handed over
sontochin and accompanying data to the Americans, who sent
everything back to the USA for analysis. It was only after this
event that resochin was rediscovered and renamed as
chloroquine in 1945, by E. K. Marshall.30 The CQ’s superior
antimalarial properties were soon recognized, and it was
designated the antimalarial drug of choice due to its high
efficacy, low cost, and tolerable adverse effects.5b
CQ is a weak diprotic base that accumulates in the acidic FV
of the parasite and exerts its activity through binding of free
heme and inhibition of hematin biocrystallization (hemozoin
formation), generating an inhospitable environment for parasite
survival.126 However, abusive use of CQ soon led to emergence
of CQ-resistant parasite strains. Only 15 years after
introduction of CQ as first-line antimalarial chemotherapy, in
the late 1950s, the first cases of P. falciparum resistance to CQ
were reported in Cambodia and Thailand.125 Ever since, CQ
resistance has been spreading across the globe, and currently,
CQ-resistant P. falciparum strains prevail in endemic areas,
except in the Caribbean and Central America.127 Recent studies
have associated parasite’s resistance to CQ to genetic changes
in transporters, the P. falciparum CQ resistance transporter
(PfCRT), and the P. falciparum multidrug resistance protein-1
(PfMDR1), which decrease the accumulation of CQ at its site
of action, the parasite’s acidic FV.128
Since the rebirth of resochin as CQ, several variations around
its 4-aminoquinoline (4-AQ) nucleus and side chain were
performed in order to prepare a superior antimalarial drug. This
effort was substantially intensified after emergence of parasite
resistance to CQ, in search for structural modifications that
would overcome PfCRT- and PfMDR1-mediated resistance.129
From these studies, several novel 4-AQ-based antimalarial
candidates emerged, among which amodiaquine (AMQ) stood
out: this phenyl-substituted analogue of CQ (Figure 44) was
synthesized in 1948 by Burckhalter et al., and found to have an
excellent activity/toxicity profile while possibly sharing with
CQ the mechanism of antimalarial action.129,130 AMQ soon
entered into the clinics, but its employment was restricted due
to side effects such as agranulocytosis and hepatitis associated
with its prophylactic use, which ended up by leading WHO to
withdraw its recommendation as monotherapy in the early
1990s.131 As amodiaquine is effective against several CQ-
resistant strains, this drug remains an important component of
current antimalarial combination therapies, being used together
with artesunate.132 In the early 1960s, another 4-AQ-based
Scheme 3. Possible Mechanism for Trioxane Unit
Degradationa
aConditions: FeBr2 (1 equiv); THF; rt.
123
Figure 42. QN-based hybrids developed by Gomes and co-workers
(91).124
Figure 43. Structure of sontochin.
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compound, piperaquine (PPQ, Figure 44), was discovered as a
promising antimalarial during a drug screening campaign, and
developed for clinical use in 1973.133 Given that PPQ is a bis-4-
aminoquinoline and was active on CQ-resistant strains, it was
proposed that compounds with a bulky bisquinoline structure
might be less efficiently effluxed by CQ resistance transporters,
which was later confirmed.129,133b Although extensive use of
PPQ also ended up by translating into considerable parasite
resistance to this drug, its combination with dihydroartemisinin
was recently approved by EMA.134 By the end of the 20th
century, another encouraging approach to overcome parasite
resistance to CQ has emerged: coupling the core of CQ to an
organometallic building block, ferrocene, led to discovery of
ferroquine (FQ, Figure 44) as a promising antimalarial
candidate.135 The high efficacy of FQ as an antimalarial has
been shown against both CQ-sensitive and -resistant P.
falciparum strains in preclinical in vitro and in vivo studies,
and currently, this compound is undergoing clinical evaluation
as monotherapy and in combination with artesunate.136 Other
encouraging late 20th century development on CQ-based
antimalarials should be highlighted: after varying the
diaminoalkyl side chain at position 4 of the CQ’s quinoline
core, Krogstad and co-workers demonstrated that compounds
with side chains longer than seven and shorter than four
carbons were active against CQ-sensitive, -resistant, and
multidrug resistant P. falciparum, with IC50 values ranging
from 40 to 60 nM against the resistant K1 strain.137 One such
compound, AQ-13 (92, Figure 44), has already undergone
phase I clinical trials, showing minimal difference in toxicity
compared to CQ. Though dose adjustment is required, as AQ-
13 exhibited increased clearance as compared to CQ, efficacy
studies are being conducted in Mali.7,138
5.2. Current Chloroquine-Inspired Antimalarial Leads
Regardless of the large amount of work performed in the last
quarter of the 20th century to improve CQ antimalarial efficacy,
and the promising results thereof, no new 4-AQ antimalarial
has entered the clinics since PPQ was brought to the clinical
setting. Moreover, none of the current first-line antimalarial
therapies in areas where CQ-resistant strains prevail was proven
to supersede CQ’s advantageous safety and cost. Therefore,
many antimalarial drug researchers worldwide keep focusing on
the development of new CQ surrogates, building on the 4-AQ
pharmacophore. The main structural modifications carried out
today consist on the generation of CQ- and AMQ-based
compounds, bis-4-AQ, organometallic 4-AQ, and, more
recently, hybrid constructs embedding the 4-AQ motif. As
some reviews on the subject prior to the 21st century can be
consulted,129,139 this section will mainly focus on novel
compounds reported after 2000 as displaying potent anti-
malarial activity.
5.2.1. Chloroquine-Based Compounds. Many research
groups have worked on the design of CQ derivatives, leading to
well-established SAR of their parent compound.140 For
example, studies performed by Egan et al. suggested that (i)
the aminoalkyl side chain is necessary for strong antiplasmodial
activity; (ii) the 7-chlorine substituent is crucial for efficient
inhibition of hemozoin formation; and (iii) the 4-AQ core is
responsible for complexing ferriprotoporphyrin IX, Fe(III)-
PPIX (Figure 45).140c,d Similarly, Krogstad and co-workers
identified four structural features related to activity against both
CQ-sensitive and -resistant parasites (Figure 45): (i) a
protonable nitrogen at position 1 and at the end of the side
chain; (ii) a 4-AQ core without alkyl substituents; (iii) a
halogen atom at position 7 (Cl preferred, Br or I tolerated, but
not F); and (iv) a wide tolerance for terminal tertiary amine
Figure 44. Major antimalarial 4-AQ candidates that emerged from CQ.
Figure 45. Main SAR established for antimalarial 4-AQ.
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functionality.140a They also observed that compounds with a
side chain length of ≤3 or ≥10 displayed better activity against
CQ-resistant strains.140a
The aforementioned promising results of AQ-13 reported by
Krogstad’s group motivated several researchers to pursue short
side chain analogues of CQ.141 In this context, Guy et al.
developed a synthetic pathway to obtain a moderate library of
side chain modified 4-AQ 93 (Scheme 4).141d SAR of these
derivatives demonstrated that when one of the alkyl
functionalities of the terminal amine was held constant as a
propyl (such 93a series), compounds displayed activity at least
comparable to their parent compound against CQ-sensitive
strain 3D7, and superior against CQ-resistant strains W2 and
Dd2. However, no significant activities were observed when a
benzyl group was held constant (such as in 93b series). Guy et
al. also worked on the synthesis and evaluation of 4-AQ
analogues with diverse substitutions at the C-5, C-6, C-7, and
C-8 positions of the quinoline ring 94.141c Compounds were
obtained following the multistep procedure (Scheme 4).
Initially, the condensation of the appropriate aniline with
Meldrum’s acid and trimethyl-ortho-formate was carried out.
Subsequently, the ene-amines were subject to microwave
irradiation, and the resulting hydroxyquinolines were trans-
formed into 4-chloroquinolines using phosphorus oxychloride
in reflux. Compounds 94 were finally obtained by a
nucleophilic addition of the respective side chain. The side
chains used were (N,N-diethyl)-1,4-diaminopentane and (N,N-
diethyl)-1,3-diaminopropane, with the latter known to restore
activity against CQ-resistant parasites.141c All compounds
displayed better activities against 3D7 (EC50 = 9−115 nM)
than W2 (EC50 = 50−309 nM) P. falciparum, while compounds
presenting the shorter side chain were more active, especially
against the CQ-resistant W2 strain. Derivatives 94 with
substituents located at the 6- and/or 7-position of the quinoline
heterocycle performed generally better against both strains.
Active substitutions tended to be small electron withdrawing
groups such as 7-CF3; 6-Me,7-Cl; 6-CF3; and 6-OCF3. In
general, compared to their parent compound, none of the
derivatives with the side chain of CQ presented better activities
against both CQ-sensitive and CQ-resistant strains.141c
Further work carried out by Guy et al. demonstrated that the
incorporation of an intramolecular hydrogen bond in the side
chain promotes the antimalarial potency of the compounds
against the CQ-resistant W2 strain.141b Particularly, compounds
presenting variations of the α-aminocresol moiety (95a−h,
Figure 46) displayed an IC50 below 5 nm against P. Falciparum
W2. Additionally, SAR demonstrated that compounds contain-
ing the propylalkyl and butylalkyl linkers were generally more
potent than those with cyclic linkers.
Later, the same researchers synthesized a set of 7-substitued-
4-AQ using as substituents diarylethers, biaryls, and alkylaryls
(correspondingly compounds 96−98 in Figure 47).141a A fixed
propyl spacer between the distal end of the side chain and the
quinoline core was chosen by Guy et al., as it was previously
found to be active in CQ-resistant parasites. Results obtained
showed good antimalarial activity against the CQ-sensitive 3D7
strain, with EC50 values ranging from 1 to 1363, 8 to 1154, and
4 to 720 nM for diaryl ether, biaryl, and alkylaryl families,
respectively. However, the biaryl series was the only one
displaying EC50 values below 50 nM against drug resistant K1
Scheme 4. Synthetic Pathway Developed by Guy et al. To Obtain (a) Side Chain Modified 4-Aminoquinoline 93 and (b)
Quinoline Modified 4-Aminoquinoline Derivatives 94141c,d
Figure 46. Side chain modified 4-aminoquinoline derivatives 95
developed by Guy et al.141b
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parasites while presenting SI values ranging from 22.7 to 261.9
(SI = EC50 HepG2/EC50 K1).
141a
Most of the compounds developed by Guy et al. were further
used in in silico, in vitro, and in vivo absorption−distribution−
metabolism−excretion−toxicity (ADMET) profiling in order to
select leads for further development into antimalarial
candidates.142 In vitro assays suggested that converting the
CQ side chain to a secondary amine increased the antimalarial
activity of the compounds and improved their pharmacokinetic
(PK) properties. In vivo studies identified two lead molecules,
99 and 100 (Figure 48), already found to display potent in vitro
efficacy (IC50 = 5.6 nM and 17.3 nM, respectively for the CQ-
resistant W2 strain), which presented low risk for drug−drug
interactions, improved ADMET properties, and PK profiles
suitable to pursue these compounds in future clinical trials.142
Another strategy used to enhance activity against parasite
resistance is the incorporation of a biologically interesting motif
in the side chain of 4-AQ derivatives.104,143 Bavari et al.
identified highly potent derivatives 101 and 102 (Figure 49)
against malaria by synthesizing and evaluating a series of CQ
analogues containing a steroidal or adamantine moiety.143d SAR
demonstrated that the use of the amide functionality to link the
4-AQ either to the steroidal or adamantine motif did not favor
the antiplasmodial activity of the derivatives, while derivatives
with two ionizable nitrogens presented the most potent
activities. Two of the most active derivatives of series 101
(101a,b) displayed highly potent activity against CQ-resistant
W2 strain (IC50 = 3.38 and 5.74 nM, respectively). Although
not as active, two 102 derivatives (102a−b) inhibited
development of CQ-resistant P. falciparum W2 parasites with
IC50 values of 8.40 and 12.10 nM, respectively.
Katti et al. have also worked on the development of CQ
analogues with biologically relevant motifs as potential
antimalarials.141g,144 They investigated the antimalarial activity
of CQ derivatives presenting a thiazolidin-4-one nucleus at the
distal end of the side chain.144a Unlike what was proposed by
Krogstad et al.,140a these results suggest that the basicity of the
side chain nitrogen is not essential for the antimalarial activity
of the compounds, since derivatives 103−105 (Figure 50)
presented moderate to good activity (IC50 = 0.013−7.153 μM)
against the CQ-sensitive NF54 strain. Two of the most active
compounds, 103a and 105a, were tested in vivo (daily
Figure 47. General structure of 7-diarylether- (96), 7-biaryl- (97), and
7-alkylaryl-4-AQ (98) derivatives developed by Guy et al.141a
Figure 48. Structure of two lead 4-AQ derivatives (99 and 100)
developed by Guy et al.142
Figure 49. 4-AQ derivatives containing a steroidal (101) or
adamantine (102) moiety.143d
Figure 50. 4-AQ analogues (103−105) developed by Katti et al.144a
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intraperitoneal dose of 30 mg/kg during 4 days) in P. yoelli
infected mice. The compounds suppressed 76 and 81%
parasitemia on day 4, respectively, and both presented a
mean survival time of 15 days.144a
Based on these results, Katti and co-workers decided to
synthesize a series of thiourea derivatives 107.141g Initially, the
desired [3-(7-chloroquinolin-4-ylamino)propyl]dithiocarbamic
acid methyl ester (106) was obtained through a one pot
reaction of N-(7-chloroquinolin-4-yl)propane-1,3-diamine and
carbon disulfide followed by the respective methylation using
dimethyl sulfate (Scheme 5). Finally, the resulted product was
subjected to a nucleophilic substitution reaction with the
appropriate amine (Scheme 5). All derivatives inhibited β-
hematin formation. The most active compound 107a displayed
superior activity than CQ with an IC50 of 23.9 and 14.1 nM
against the P. falciparum CQ-sensitive (D6) and CQ-resistant
strain (Dd2), respectively. These results were in accordance
with the previous findings of the group that the basicity of the
nitrogen of the distal end of the side chain of CQ derivatives is
not essential for antimalarial activity.141g
Following the same line of thought, Chauhan et al. recently
reported a series of tetrazole derivatives of CQ.143c Compounds
were synthesized in two reaction steps (Scheme 6). Initially, the
appropriate amine was obtained through the nucleophilic
reaction of the corresponding diaminoalkane, piperazine, or p-
phenylenediamine with 4,7-dichloroquinoline. The amine
obtained was then subjected to a TMSN3−Ugi multi-
component reaction. SAR on these compounds demonstrated
that their activity was greatly influenced by the linker, as
substitution of the flexible aliphatic linker by an aromatic ring
led to significant increase in the activity of the derivatives. Two
of the most active compounds (108a and 108b) displayed
promising in vitro activities against the CQ-sensitive 3D7 strain
(IC50 = 10.66 and 11.78 nM, respectively) and the resistant K1
strain (IC50 = 142.9 and 233.7 nM, respectively), performing
better than the parent drug and presenting high SI values
(4616.44 and 2332.43, respectively). Furthermore, after the oral
administration of a daily dose (100 mg/kg) during 4 days to P.
yoelli infected mice, these two compounds exhibited 99.99%
parasite suppression on day 4, and 60% of survival on day 28.
Preliminary in vivo PK studies performed by the same group
suggested that compound 108b could be a better candidate
drug than 108a.143c
Several efforts have been made to obtain CQ derivatives
capable of overcoming drug resistance and to identify structural
features to take into account in the design and optimization of
potent antimalarial agents.145 Gemma et al. synthesized a series
of hydrazone derivatives 109 (Figure 51) and tested their
antimalarial properties.145a,146 The results showed that CQ
derivatives presenting a methoxy in the 8-position (109a−b) or
a methylenedioxy moiety in the 6,7-position (109c) of the
Scheme 5. Synthetic Pathway To Obtain 4-AQ Derivatives
107 Developed by Katti et al.141g
Scheme 6. Synthetic Pathway To Obtain Tetrazole
Derivatives of CQ (108) Developed by Chahan et al.143c
Figure 51. 4-AQ/hydrazone derivatives 109 and their analogues 110
developed by Gemma et al.146
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quinoline ring displayed lower activity (IC50 values ranging
from 163 to 356 nM against P. falciparum W2) than those
compounds with a methoxyl or a chlorine group (109d−g) in
the 6- and 7-position (IC50 = 58.3−128 nM against P.
falciparum W2), respectively. SAR studies demonstrated that
the introduction of electron-donating moieties such as alkoxy
or alkylamino groups at the para position in the arylidene motif
did not significantly influence the antimalarial activity,146 while
the replacement of the arylidene moiety by a heteroarylidene
functionality led to a decrease in the antiplasmodial activity.
Later, Gemma and co-workers showed that the hydrazine
moiety is critical for antimalarial activity, as derivatives 110
(Figure 51), bearing either an acylhydrazino or sulfonylhy-
drazino linker, presented a complete loss of activity.146 Two of
the compounds displaying the best activity in vitro (109f−g
with IC50 values of 16.4 and 39.6 nM against P. falciparum K1;
IC50 = 260 nM for CQ) and moderate toxicity (ED50 values of
19.5 and 152 μM against KB cells) presented promising in vivo
activity (daily intraperitoneal dose of 30 mg/kg) by suppressing
83 and 71% of parasitemia at day 4.146 β-Hematin inhibitory
assays carried out suggest the existence of an alternative MOA
for the antimalarial activity of these CQ derivatives.146
Roepe et al. have also worked on the development of side
chain modified CQ analogues to overcome parasite resistance,
by synthesizing and evaluating compounds 111−113 (Figure
52) against CQ-sensitive and CQ-resistant parasites.141f,147 A
better performance of compounds 111 over compounds 112
against the P. falciparum Dd2 parasites suggested that the
presence of a tertiary central amino group in series 111 is
essential for the activity against the CQ-resistant strain. In
particular, compounds 111a−b are potent antiplasmodials and
equally effective against both CQ-sensitive (HB3; IC50 = 27.3
and 21.2 nM, respectively) and CQ-resistant (Dd2; IC50 = 31.2
and 28.1 nM, respectively) strains. Further studies performed
by the same group showed that, although the substitution of the
amino group in the 4-position of the quinoline ring by alkylthio
or alkoxy substituents (113, Figure 52) increases selectivity
against CQ-resistant over CQ-susceptible parasites, it decreases
the antiplasmodial activity of the compounds.141f According to
pKa determinations, the introduction of these two moieties into
the 4-position of the quinoline ring affords effective monoprotic
weak bases at physiological pH. Thus, Roepe et al.
hypothesized that since CQ analogues 113 with X = NH are
diprotic bases, they probably accumulate better in the FV,
which could explain the generally better inhibitory activities
displayed by these analogues when compared to the CQ
derivatives 113 with X = O or X = S (Figure 52).
Wolf et al. synthesized and evaluated different 4-amino-7-
chloroquinolyl-derived amides, sulfonamides, ureas, and thio-
ureas 114−118 (Figure 53) against CQ-sensitive (HB3) and
CQ-resistant (Dd2) strains.148 Most of the derivatives
presented activity in the submicromolar range and low
resistance indices [IC50(HB3)/IC50(Dd2)]. Although none of
the derivatives was as active as their parent compound, the
sulfonamide analogue 116a displayed improved activity against
Dd2 strain parasites (IC50 = 23 nM).
Recent studies keep demonstrating that modification of CQ
side chain continues to be a validated strategy to obtain potent
antimalarials.149 For example, Sparatore and co-workers
obtained potent antimalarial CQ derivatives by incorporating
a heteroaromatic group in the side chain (119−120 in Figure
54).149b Most synthesized compounds 119−120 displayed
activity in the nanomolar range against CQ-susceptible D10
(IC50 = 5.5−2656.6 nM) and CQ-resistant W2 (IC50 = 20.9−
4219.9 nM) P. falciparum parasites. The most interesting
compounds, 119a−b and 120a, were more active (IC50= 11.8−
Figure 52. 4-AQ derivatives 111−113 developed by Roepe et
al.141f,147
Figure 53. General structure of CQ-based amides (114−115),
sulfonamides (116−117), ureas and thioureas (118) developed by
Wolf and co-workers.148
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13.4 nM against D10 strain and IC50= 20.9−26.5 nM against
W2 strain) than CQ and had moderate cytotoxicity (IC50 =
6.7−28.6 μM against HMEC-1 cell line). Further studies
carried out by Med́ebielle et al. demonstrated that the
introduction of a γ-lactam motif into the side chain of CQ
resulted in potent compounds 121 (Figure 54) against CQ-
sensitive (3D7) and CQ-resistant (W2) parasites, with IC50
values ranging from 19 to 50 nM.149c Results showed than none
of the tested compounds 121 presented cytotoxicity when
evaluated against human umbilical vein endothelial cells at a
concentration up to 100 μM. SAR revealed that the length of
the spacer has a significant effect on the antiplasmodial activity;
generally, a propyl spacer was preferred over butyl or hexyl
spacers. According to the authors, additional studies are being
performed, such as the evaluation against multiple P. falciparum
strains, in vivo efficacy of the derivatives, and definition of the
MOA of the compounds.
After Riscoe and co-workers discovered that the early CQ
surrogate, sontochin, retains in vitro activity against P.
falciparum CQ-resistant strains, they synthesized derivatives
122 (Figure 55), with variations of the side chain and with alkyl
or aryl substituents at C-3 of the quinoline ring to enhance
activity against drug-resistant parasites.150 Results showed that
the introduction of a lipophilic aromatic group at the 3-position
of the quinoline ring leads to a significant increase in in vitro
and in vivo activity against multidrug-resistant P. falciparum
strains and murine P. yoelii infections, respectively. Indeed,
compound 122a exhibited low nanomolar activities against
CQ-sensitive (IC50 = 0.9 nM on D6 strain) and multidrug-
resistant strains (IC50 = 1.4 nM on Dd2 strain) and in vivo
efficacy in P. yoelli infected mice that were superior to CQ.
Compound 122a presented 30-day cures in all animals at 16
and 64 mg/kg (oral dose during 4 days) without signs of
distress or toxicity. Riscoe et al. are currently investigating
possible explanations to the enhanced performance of
compound 122a over CQ in the murine model, such as its
conversion into active metabolites in vivo or enhanced
metabolic stability and PK in mice.
5.2.2. Amodiaquine-Based Compounds. The side chain
of AMQ contains a 4-aminophenol group that is oxidized by
one or more cytochrome P450 enzymes to a quinoneimine,
which underlies AMQ’s toxicity.151 Consequently, several
AMQ analogues have been studied in order to avoid
quinoneimine formation.129
Sergheraert et al. worked on the synthesis and evaluation of
the antimalarial activity of 4-anilinoquinoline analogues lacking
the phenolic hydroxyl group (compounds 123−125 in Figure
56).152 These analogues contained two basic side chains at the
3′- and 5′-positions which hindered the 4′-site from impeding a
possible nucleophilic addition even if 4′-hydroxylation occurred
in vivo. The compounds presented, in general, lower activities
compared to AMQ. Also, the replacement of the terminal
Figure 54. CQ derivatives containing a heteroaromatic (119−120)
and γ-lactam (121) motif in the side chain.149b,c
Figure 55. General structure of sontochin derivatives 122 developed
by Riscoe et al.150
Figure 56. AMQ derivatives 123−125 developed by Sergheraert and
co-workers.152
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methylpiperidine ring at the 3′-position of series 123 by a
chlorine, a hydroxyl, or an aromatic ring led to the decrease of
antimalarial activity. The most promising compound of the
series (125a) displayed an IC50 value of 9.5 nM in vitro against
the P. falciparum CQ-resistant FcB1R strain, and presented
excellent performance in vivo on P. berghei infected mice (daily
intraperitoneal dose of 40 mg/kg for 4 days), by suppressing
100% parasitemia at day 4 and showing decreased cytoxicity
upon mouse macrophage as compared to AMQ. However, to
the best of our knowledge, no further studies on this promising
compound were reported yet.
Equally aiming at avoiding oxidation of AMQ-based
compounds to quinoneimines, O’Neill and colleagues synthe-
sized a series of analogues 126a−j (Figure 57) which possess
the 3′ hydroxyl and the 4′ Mannich side-chain group of AMQ
interchanged.153 Several derivatives presented potent antima-
larial activity (low nanomolar range) against both sensitive
(HB3) and multidrug resistant (K1) P. falciparum strains. One
of the most active compounds, named isoquine (126a),
inhibited in vitro development of K1 parasites with an IC50
value of 17.63 nM, and displayed an excellent oral in vivo ED50
and ED90 activity of 1.6 and 3.7 mg/kg, respectively, on P. yoelii
infected mice.153 Unfortunately, the development of isoquine as
an antimalarial was compromised due to the metabolic cleavage
of the N-diethylamino group originating dealkylated metabo-
lites.154 Still, O’Neill and colleagues demonstrated the superior
PK and pharmacodynamics (PD) profile of the most
metabolically stable compound of the series 126b, as compared
to 126a, in four animal species.154 In spite of the excellent
exposures and near quantitative oral bioavailabilities in animal
models, development of compound 126b was discontinued due
to insufficient demonstration of drug safety superior to CQ.155
Those authors kept on searching for a back-up compound for
126b, through the study of a series of AMQ analogues where
the 4′-hydroxyl functionality was replaced by either fluorine or
chlorine, and demonstrated that such substitution confers
metabolic stability to the compounds.156 Accordingly, com-
pound 127 was identified as a candidate for further clinical
studies, since it presented potent activity against CQ-resistant
parasites (IC50 = 22 nM against P. falciparum K1 strain), low
toxicity in in vitro studies (IC50 = 385 μM against rat
hepatocytes), moderate to excellent oral bioavailability, and
acceptable safety profiles.156 To the best of our knowledge, no
further reports on this promising compound have emerged up
to today.
Further works have been carried to obtain AMQ surrogates
unable to undergo P450 oxidation to produce quinoneimine
metabolites.157 Moreira et al. synthesized a series of N-Mannich
base derivatives 128 (Scheme 7) which displayed activity
against the multidrug resistant Dd2 strain (IC50 = 15−31 nM)
higher or comparable to the parent drug (IC50 = 30 nM).
157
Compounds 128a−f were obtained by reacting the convenient
tertiary N-chloromethylamide with the sodium salt of AMQ
(Scheme 7). The most active compound was the p-nitrophenyl-
substituted derivative 128e (IC50 = 15 nM against Dd2 strain),
which was also very stable in human plasma. Results showed
that the antiplasmodial activity is not significantly influenced by
the physicochemical properties of the amide functionality.
Further preclinical or clinical studies on these N-Mannich base
derivatives of amodiaquine have not been yet reported.
Additional work carried out by Lin and co-workers originated
AMQ analogues with general formula 129 (Figure 58).158 The
results showed that the new analogues were generally better or
Figure 57. AMQ derivatives 126 and 127 developed by O’Neill and
co-workers.153,156
Scheme 7. Synthetic Procedure Used by Moreira and Co-
Workers To Obtain AMQ Analogues 128157
Figure 58. AMQ analogues 129 developed by Lin and co-workers.158
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comparable to their parent compound against CQ-sensitive
(Dd6) and CQ-resistant (W2) strains, with IC50 values in the
range of 0.3−130 ng/mL. The in vitro cytotoxicity of derivatives
129 was also assessed against macrophage line J774, obtaining
IC50 values ranging from 0.75 to 11.6 μg/mL. Despite the
potent in vitro antimalarial activity displayed by the most active
derivative 129a (IC50 = 0.3 and 0.4 ng/mL against Dd6 and W2
strains, respectively), the compound did not show significant in
vivo activity against P. berghei at doses up to 192 mg/kg, which
could be explained by its poor solubility in polar organic
solvents and water.
Melnyk et al. synthesized and evaluated carbamate, amide,
ester, and amine analogues of AMQ (130−133, Figure 59).159
All the derivatives presented comparable or superior activity
compared to the parent drug. Accordingly, in the carbamate
series 130, the authors devised that (i) the presence of a
terminal tertiary amine improves the antimalarial activity of the
compounds, (ii) cyclic or acyclic terminal amines present the
same range of activity, and (iii) the presence of an additional
electron-withdrawing atom in the side chain decreases activity;
similar SAR were observed in the amide series 131. In addition,
Melnyk et al. found that tertiary amines are preferred over
secondary amines. Contrary to results found in the carbamate
series, more than two methylene groups clearly decrease
activity in the amide derivatives. In the ester series, cyclic amine
132 seems to be preferable, but such was not observed in the
amine series 133. Compound 131h was the most active overall,
as it was highly potent against the three P. falciparum strains
tested (IC50 = 38.4, 19.2, and 51.2 nM against Thai, FcB1R, and
K1, respectively), presented a high SI (833), and displayed
reasonable in vivo activity.159
More recent works have been carried out to also circumvent
the formation of toxic AMQ metabolites while retaining/
improving their antiplasmodial activity.160 Carvalho et al.
reported a series of compounds where the AMQ core was
conjugated either with furoxan or nitrooxy NO-donors (134,
Figure 60) based on the idea that NO seems to play an
important role in the pathogenesis of the malaria parasite.160a
Most of the derivatives presented antimalarial activities
comparable to that of the parent compound. The most active
compound, 134a, displayed an IC50 of 21 nM against CQ-
resistant parasites (W2) and total cleared parasitemia in vivo
against P. berghei ANKA after 72 h. However, results also
demonstrated that NO-donor properties did not significantly
contribute to the antiplasmodial activities exhibited by the
compounds.
5.2.3. Piperaquine-Inspired Compounds. Bis-4-amino-
quinolines are compounds that, like PPQ, contain two 4-AQ
cores. As mentioned earlier, PPQ’s use declined in the 1980s
after the emergence of P. falciparum strains resistant to this
drug.161 However, PPQ’s relevance in antimalarial chemo-
therapy was rediscovered in the following decade, as it was
found suitable to be combined with artemisinin derivatives.161
This discovery triggered the search for novel bis-4-AQ in the
past decade of the 20th century. While the antimalarial activity
of many such novel compounds has been reported earlier, and
their role in malaria chemotherapy has been extensively
reviewed,162 only a few cases have been reported in the past
decade, as next reviewed in this section.
Deady et al. synthesized a series of bis-4-AQ that contained a
(CH2)n linker in the 2-position of the 4-AQ ring joining the
two heteroaromatic rings (135, Figure 61).163 The results
showed that the linker influenced antimalarial activity, which
increased with the increase of spacer length. The most active
compound 135c displayed IC50 values of 43 and 17 nM against
CQ-sensitive (D10) and CQ-resistant (K1) strains. As
compared to CQ, the activity of 135c was identical, or 12-
fold higher, against P. falciparum D10 or K1, correspondingly.
Compound 135c was demonstrated to be an efficient inhibitor
Figure 59. AMQ-based carbamate (130), amide (131), ester (132)
and amine (133) derivatives developed by Melnyk et al.159
Figure 60. General structure of AMQ derivatives 134 developed by
Carvalho et al.160a
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of β-hematin formation, similar to CQ, suggesting this could be
the mechanism responsible for its antimalarial activity.
More recently, N’Da et al. reported a series of bis-4-AQ
containing polyamine linkers.164 Most compounds 136 (Figure
62) were as potent as CQ against a CQ-susceptible (D10; IC50
= 37.38−128.59 nM) strain, while displaying significantly
superior activity against multidrug resistant (Dd2; IC50 =
35.49−72.88 nM) parasites. Derivatives 136 exhibited cytotox-
icity upon Chinese hamster ovarian cell line, with IC50 values
ranging from 2.61 to 12.97 μM. The authors hypothesized that
the increased antimalarial activity against resistant P. falciparum
strains might be due to the increased number of protonation
sites, which in turn could induce a higher accumulation inside
the parasite’s acidic FV.
Bavari and colleagues recently reported a very different family
of bis-4-AQ (compounds 137, Figure 63).165 These com-
pounds were first discovered as inhibitors of the botulinum
neurotoxin serotype A light chain. However, the structural
similarities of these molecules with CQ and derivatives,
motivated Bavari et al. to evaluate them against CQ-sensitive
and CQ-resistant strains D6 and W2, respectively. Results
showed that all compounds inhibited parasite growth at
nanomolar concentrations. Compounds whose side chains
had a primary amino group were the least effective, with
antimalarial activity increasing with increased substitution on
the basic side chain nitrogens.165 Also, introduction of
morpholine moieties further improved antiplasmodial activity.
The most potent antimalarials, compounds 137j and 137l−m,
displayed IC50 values of 6.01, 5.23, and 5.93 nM against D6
strain and 3.48, 2.00, and 6.12 nM against W2 strain,
respectively, being more potent than CQ. The cytotoxicity of
the compounds was evaluated in a rat macrophage cell line,
obtaining IC50 values in a range of 7−10 μM. Furthermore,
derivative 137j was also effective when administered orally in a
rodent malaria model infection, but additional studies are
needed to fully assess the potential of these compounds as
antimalarials.
5.2.4. Organometallic 4-Aminoquinolines. Metal com-
plexes have found therapeutic application against several
distinct pathologies.166 As mentioned earlier, ferroquine (FQ)
was the first organometallic compound to enter clinical trials as
a potential antimalarial drug candidate.136 This exciting
breakthrough encouraged an intense interest in the design
and synthesis of other organometallic 4-AQ derivatives.167
Biot and co-workers synthesized compounds 138−139
(Figure 64) in order to evaluate the best position at which to
place the ferrocene moiety: (i) as a substituent of the amino
group at the distal end of the CQ side chain in series 138 or (ii)
as a part of the linker between the two amino groups of the CQ
side chain in series 139.168 Although most of the compounds
138 exhibited low IC50 (below 100 nM) against CQ-sensitive
(HB3) and CQ-resistant (Dd2 and W2) strains, they presented
high IC90 values (>500 nM), suggesting they will possibly be
ineffective to strongly inhibit P. falciparum parasites. In series
139, only compounds with alkyl substituents at the amino
group at the distal end of the side chain presented low IC50 and
IC90 (<40 nM) values against all tested parasite strains. This
study demonstrated that compounds with the ferrocene moiety
Figure 61. General structure of bis-4-AQ derivatives 135 developed by
Deady and co-workers.163
Figure 62. General structure of bis-4-AQ derivatives 136 developed by
N’Da and co-workers.164
Figure 63. General structure of novel bis-4-AQ derivatives, 137,
developed by Bavari and colleagues.165
Figure 64. General structure of FQ derivatives 138 and 139 developed
by Biot and co-workers.168
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covalently flanked by a 4-AQ and an alkylamine group are more
prone to display potent antimalarial activity.
Based on the fact that glutathione reductase inhibitors were
developed to reverse CQ resistance and to combat malaria,169 a
few years later, the same group reported a series of compounds
that linked together an FQ analogue with a glutathione
reductase inhibitor.170 Derivatives 140−142 (Figure 65) were
evaluated against CQ-sensitive (NF54) and CQ-resistant (K1)
strains, and it was found that compounds 140 were the most
active in vitro, with IC50 values ranging from 26.7 to 104.2 nM.
Regardless of the choice of the alkyl substituent on the amino
group at the distal end of CQ side chain, compounds 140 were
more active on both strains than their parent glutathione
reductase inhibitor. However, their antiplasmodial activity was
slightly lower compared to parent FQ. Biot et al. hypothesized
that this decrease in antiplasmodial activity might be due to the
fact that both the side chain and amide bond in FQ are cleaved
in the course of oxidative metabolism in the parasite’s FV.170
Further FQ analogues have been reported, such as those by
Davioud-Charvet and co-workers.171 Compounds 143 (Figure
66) displayed potent antimalarial activity, with IC50 and IC90
values in the low nanomolar range (<100 nM). In addition,
these derivatives were also found to present high cytotoxicity
(IC50 = 1−64 μM) against the human lung cell line MRC-5.
The authors then observed that compounds 143 show high
DNA binding properties, thus suggesting that these FQ
derivatives may be more appropriate for further development
as antiproliferative agents.171
Further recent reports on 4-AQ organometallic derivatives
include Nordlander’s work.172 Based on the idea that
cymantrene is stable in water and air, Nordlander et al.
conjugated cymantrene with CQ analogues (144−145, Figure
67) and evaluated their activity against malaria. In addition, to
assess the influence of the metal center on the antiprotozoal
activity, they included a cyrhetrene analogue in the study.
Compound 145 displayed good activity (IC50 = 0.16 μM)
against the CQ-susceptible (D10) strain but did not present
any activity against the multidrug resistant Dd2 strain up to 2
μM. On the contrary, the cymantrene derivative 144a
presenting an amide linker was active against both strains
with IC50 values of 0.27 and 0.37 μM, respectively. The in vitro
cytotoxicity of both compounds was assessed upon human
macrophage cells with IC50 values of 7.4 and 4.6 μM for 144a
and 145, respectively. No significant effect in antimalarial
activity was observed when replacing manganese for rhenium;
still, none of the compounds presented better antiprotozoal
activity than CQ.
5.2.5. 4-Aminoquinoline Hybrids. As mentioned before,
a recently proposed strategy to combat parasite resistance is the
development of hybrid compounds also known as dual-action
drugs.22,123 This, in addition to artemisinin-based combination
therapies as first-line treatment in malaria chemotherapy, led
Meunier’s group to develop the novel hybrid compounds
trioxaquines (compounds 146a−d, Figure 68), obtained by
covalently joining a trioxane moiety, meant to mimic the
alkylating ability of artemisinin, with the 4-AQ core of CQ,
known to easily penetrate within infected red blood cells.173 All
trioxaquines were tested against FcM29 and FcB1 CQ-resistant
strains and the Nigerian CQ-sensitive P. falciparum strain,
presenting IC50 values ranging from 2 to 86 nM.
173b The
authors observed that the biological results obtained for the
CQ-sensitive strain were dependent on the length of the spacer
between the 4-AQ and trioxane motifs, with a shorter chain
(146b) being preferred over the longer ones (146a,c). Among
the tested trioxaquines, the dicitrate 146d (IC50 = 8−21 nM)
and its base analogue 146b (IC50 = 2−18 nM) were the most
active, presenting better antimalarial activities than each of the
parent compounds.
Encouraged by the high activity displayed by the hybrid
146d, Meunier and co-workers synthesized and evaluated the
antimalarial activity of a new series of trioxaquines (146e,f and
147, Figure 68).174 This study aimed at understanding the
Figure 65. General structure of FQ derivatives linked to glutathione
reductase inhibitor, 140−142, developed by Biot and co-workers.170
Figure 66. General structure of FQ derivatives 143 developed by
Davioud-Charvet and co-workers.171
Figure 67. General structure of CQ conjugates with cymantrene (144)
and cyrhetrene (145) developed by Nordlander and co-workers.172
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influence of different structural parameters, namely the length
of the linker between the trioxane and 4-AQ motifs (146e,f)
and the nature of the starting diene (147). These molecules
presented antimalarial activities in the low nanomolar range
(IC50 = 5−181 nM) against both CQ-sensitive and resistant
strains. Results indicated that no significant influence was
observed in compounds activity when varying the size of the
linker, except for activities on Nigerian CQ-sensitive strain, as
already reported for compounds 146a−d.173b,174 Similarly, no
significant change was detected regarding the nature of the
starting diene. Still, compound 147b presented the best
activities (IC50 = 5−19 nM), and was thus selected for in
vivo tests, which revealed that a daily intraperitoneal dose of 20
mg/kg for 4 days led to parasitemia clearance without
recrudescence.174 It was later confirmed that compound 147b
was also active against young (IC50 = 69 nM) or mature
gametocytes (IC50 = 67 nM) and presented the absence of
toxicity for both human cell lines and mice.175 However,
despite its promising profile, compound 147b was not
considered for further development due to its high number
of chiral centers. In view of this, a joint project between
PALUMED, Sanofi-Aventis, and the French National Center
for Scientific Research focused on the synthesis of simpler
third-generation trioxanes (148, Figure 69) and their in vitro
evaluation against CQ-sensitive and CQ-resistant P. falciparum
strains.122 Among the ∼120 tested compounds, the hybrid
148a was selected for preclinical development and found to (i)
present high in vitro antimalarial activity against several P.
falciparum strains (IC50 = 7−24 nM); (ii) be curative for
infected mice, by the oral route (26−32 mg/kg); (iii) be highly
efficient in humanized infected mice; and (iv) present a good
ADMET profile. However, it appears that further development
of 148a was halted in 2010 due to restructuration of Sanofi-
Aventis.176
Lategan and colleagues have equally developed 4-AQ/
artemisinin hybrids by joining the dihydroartemisin motif to
different 4-AQ via an ether/amine bond (149 in Figure 70),
with the aim to increase the half-life of dihydroartemisin.177
Most of the tested compounds presented higher or comparable
potency against both CQ-sensitive (D10; IC50 = 12.18−201.38
nM) and resistant (Dd2; IC50 = 17.12−275.99 nM) strains than
CQ, with hybrid 149d displaying the best antimalarial activity
(IC50 = 12.18 and 17.12 nM against D10 and Dd2,
respectively). Cyclic linkers seemed to be detrimental to
antimalarial activity, as compounds with an alkyl chain generally
possessed lower IC50 values. The in vitro cytotoxicity of
derivatives 149 was also assessed against the Chinese hamster
ovarian cell line, presenting IC50 values within the range of
0.17−37.34 μM.
Somewhat similar hybrids were reported a few months later
by Chibale and co-workers, who synthesized hybrids 150
(Figure 71) by coupling dihydroartemisinin and several 4-AQ
moieties through an ether/amide bond.178 All the compounds
displayed excellent in vitro activities against CQ-sensitive (D10)
and resistant (K1) P. falciparum strains with IC50 values ranging
from 19 to 35 nM. Compound 150 was also found to share the
same MOA with both artemisinin and CQ, as the tested
Figure 68. Trioxaquine hybrid compounds 146a−f and 147 developed
by Meunier et al.173
Figure 69. Trioxaquine hybrid compounds 148 developed as a joint
project between PALUMED, Sanofi-Aventis and the French National
Center for Scientific Research.122
Figure 70. 4-AQ/artemisinin hybrids 149 developed by Lategan and
colleagues.177
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compounds displayed potent activity against β-hematin
formation and contributed to an increase in accumulation of
hemoglobin within the parasites. Nevertheless, despite the
potent biological results, hybrids 150 were found to exhibit
cytotoxicity against a human cervical cancer cell-line (HeLa),
presenting lower SI values (8−26) compared to their parent
compound CQ (39).
As mentioned at the beginning of section 5.1, CQ resistance
has been associated with the membrane protein PfCRT. Based
on the identification of structurally diverse molecules as reversal
agents (RA), known to inhibit PfCRT, Peyton et al. developed
a hybrid compound linking the CQ-like moiety to a reversal
agent (151 in Figure 72).179 151 presented low nanomolar
antimalarial activity against CQ-sensitive (D6; IC50 = 2.9 nM)
and CQ-resistant (Dd2; IC50 = 5.3 nM) P. falciparum strains
and suppressed more than 99% parasitemia in P. chabaudi
infected mice via the oral route (daily dose of 64 mg/kg during
4 days).179
Encouraged by the excellent performance of 151, the same
team further searched to identify the structural factors required
for good antimalarial activity by introducing structural
modifications in 151, as depicted in Figure 73.180 All the
compounds displayed significant activity against D6 and Dd2 P.
falciparum strains (IC50 < 125 nM). The in vitro cytotoxicity
was also assessed against mouse spleen lymphocytes, obtaining
IC50 values ranging from 0.7 to 62 μM. Although compounds
with a piperazinyl linker presented the lowest activities, the
overall good results indicated that there is enough freedom to
design improved 151 analogues.
In this context, Peyton and co-workers performed a more
extensive SAR study with further changes to both the linker and
the aromatic headgroup of the RA motif originating hybrids
152 (Figure 74).181 In vitro results showed that these
compounds have high efficacy against CQ-sensitive and
resistant P. falciparum strains (IC50 = 0.9−56 nM) and that
their SI values (132−69400) are greater than the value for CQ
(122). The MOA by which 152 could exert their activity was
also assessed, and although not fully elucidated, the results
Figure 71. 4-AQ/artemisinin hybrids 150 developed by Chibale and
co-workers.178
Figure 72. Structure of hybrid compound 151 developed by Peyton
and co-workers.179
Figure 73. Structural variations introduced in structure 151.
Figure 74. Structure of hybrid compounds 152 developed by Peyton
and co-workers.181
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indicated that these compounds seem to act similarly to CQ.
This suggested that the RA motif contributes to 152 activity by
increasing their accumulation in parasites FV. Some of the
compounds were tested in vivo, and those results pointed to
hybrid 152a as a promising lead for preclinical development, as
it presented (i) low clogP value; (ii) good oral activity, and (iii)
no evident signs of toxicity. As far as we know, no further
results on these promising hybrids were reported so far.
Other potent hybrid antimalarials constituted the ones
developed by Gemma et al., who synthesized compounds
153 (Figure 75), conjugating the 4-AQ core and a clotrimazole-
like moiety.182 The synthesis and evaluation of 153 were
motivated by promising antiplasmodial activities previously
found for clotrimazole derivatives. The latter had been
synthesized based on the hypothesis that the imidazole ring
would be able to coordinate with free heme and, consequently,
to generate trityl radicals toxic to the parasite.183 Hybrids 153
were found to inhibit several P. falciparum strains with IC50
values ranging from 3.9 to 1371 nM. The results indicated that
the 4-AQ ring substituents play an important role on the
antimalarial activity, as the compounds bearing a chlorine atom
at the C7 position generally displayed better activities than their
analogues. Conjugate 153a was identified as the most active
compound of the series, displaying activity in the nanomolar
range (IC50 = 12−65 nM) against CQ-sensitive (3D7 and D10)
and CQ-resistant (W2 and Dd2) parasites, moderate in vitro
toxicity (IC50 = 213 μM against KB cells), in vivo activity (oral
administration) against infections produced by P. chabaudi and
P. berghei parasites, and promising pharmacokinetic properties.
Further optimization studies on the 4-AQ/clotrimazole
hybrids were performed by modifying the protonable hetero-
cycle in the benzhydryl functionality.184 Such led to compound
154 (Figure 76), which showed (i) better activity against β-
hematin formation compared to CQ, (ii) potent activity against
CQ-sensitive (IC50 = 17−62 nM) and CQ-resistant (IC50 =
22−58 nM) parasites, and (iii) an optimal half-life in mice.
Despite the good preliminary results, this compound was found
to cause negative effects in mice when evaluated at higher
concentrations. The Gemma group is currently working on the
optimization of this novel family of hybrids.184
The development of novel 4-AQ-based dual-action com-
pounds has also been addressed by functionalizing the lateral
chain of CQ with a triazine group, the core of cycloguanil that
is a potent inhibitor of P. falciparum dihydrofolate reductase, an
essential enzyme in the folate pathway. In 2008, Chauhan et al.
reported the synthesis of hybrids 155 (Figure 77), on which
SAR studies were conducted.111c It was found that piperidine,
cyclohexylamine, p-fluoroaniline, aniline, and morpholine
substituents in the triazine functionality are well tolerated for
the antimalarial activity of compounds 155 resulting in
nanomolar activities (IC50 = 4.43−256 ng/mL) against the
CQ-sensitive 3D7 strain, although none of the compounds
surpassed CQ activity (IC50 = 2.6 ng/mL).
111c The most active
compounds of the series, 155a−b, presented an IC50 of 7.15
and 4.43 ng/mL in vitro, respectively, and SI values of 328.61
and 481.48 (SI = IC50 VERO/IC50 3D7). Furthermore,
derivatives 155a−b were also found to suppress in vivo (daily
intraperitoneal dose of 50 mg/kg) 99.11% of parasitemia in
mice infected with P. yoelli CQ-resistant strain N-67.
The same authors further developed additional CQ/triazine
hybrids 156 (Figure 78) with antimalarial activity (IC50 = 5.2−
164.0 ng/mL) against CQ-sensitive P. falciparum 3D7 strain
Figure 75. Structure of CQ/clotrimazole hybrid compounds 153
developed by Gemma and co-workers.182
Figure 76. Structure of CQ/clotrimazole derivative 154 developed by
Gemma et al.184
Figure 77. Structure of CQ/triazine hybrid compounds 155
developed by Chauhan and co-workers.111c
Figure 78. Structure of CQ/triazine hybrid compounds 156
developed by Chauhan and co-workers.185
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comparable to that of CQ (IC50 = 5.2 ng/mL) and presenting
SI values (SI = IC50 VERO/IC50 3D7) ranging from 65.21 to
4692.08.185 The results demonstrated that the piperidine
substitution on the triazine ring enhances the antimalarial
activity of the compounds, contrary to what was observed for
compounds bearing a morpholine substituent. Unlike the
hybrids previously reported by the group, 156 did not show in
vivo activity.
Rawat et al. have also worked on the development of similar
triazine/4-AQ hybrids, such as compounds 157 (Figure 79),186
with nanomolar activities against CQ-susceptible D6 (IC50 =
0.06−0.67 μM) and CQ-resistant W2 (IC50 = 0.11−1.70 μM)
P. falciparum strains and SI values (SI = IC50 VERO/IC50 W2)
ranging from 14.7 to 227.2.186c SAR demonstrated that the
linker between the 4-AQ ring and the 1,3,5-triazine nucleus
seems to influence the antimalarial activity of the hybrids, as it
was generally observed that increasing the number of
methylene groups from two to four improves antimalarial
activity. In addition, aromatic substitution on the 1,3,5-triazine
seems to be preferred over aliphatic substitution, and the
incorporation of amino alcohol substituents with a terminal
hydroxyl functionality in the triazine core was also found to
enhance antimalarial activity.
Based on the report that astemizole is a potent inhibitor of P.
falciparum parasites both in vitro and in vivo,187 Kaiser and
colleagues engaged in the synthesis of CQ/astemizole hybrids
158−161 (Figure 80).188 With the exception of hybrid 158
bearing the conformationally constrained piperazine linker, all
the compounds were 3- to 10-fold more active than CQ and
with SI values (SI = IC50 rat L6 myoblasts/IC50 K1) higher
than 100. The best activity was obtained for 159 with an IC50 of
23 nM against CQ-resistant P. falciparum K1 strain. However,
only hybrids 160−161 (IC50 = 64 and 37 nM, respectively)
presented in vivo activity against P. berghei infected mice, with
160 reducing parasitemia comparable to CQ after the
administration of daily doses of 50 mg/kg.
Other 4-AQ-based dual-action compounds have been
obtained by joining the CQ core with another antimalarial
moiety such as aminopyrimidine, such as those reported by
Singh and co-workers (162, Figure 81).189 Most of the
compounds displayed antimalarial activity in the nanomolar
range against the CQ-resistant K1 P. falciparum strain, and SI
values (CC50 VERO/IC50 K1) ranging from 0.48 to 638. The
authors noticed that compounds with linear alkyl linkers
presented enhanced activity with the increase in length of the
linker up to 4 carbons, while longer spacers resulted in a
Figure 79. Structure of CQ/triazine hybrid compounds 157
developed by Rawat et al.186c
Figure 80. Structure of CQ/astemizole hybrid compounds 158−161
developed by Kaiser and co-workers.188
Figure 81. Structure of hybrid compounds 162 developed by Singh
and co-workers.189
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significant reduction of antimalarial activity. It was also
observed that the substitution of the methyl or ethyl ester by
the iso-propyl ester resulted in an increase of the activity against
the CQ-resistant strain, while the reverse trend was obtained
for the CQ-sensitive strain.189b Moreover, the replacement of
the diaminoalkyl side chain by a less basic alkoxy linker resulted
in lower antimalarial activity.189a The lead compound of this
series was 162a, as it showed the lowest IC50 values (18.2 and
3.6 2 nM) against CQ-sensitive 3D7 and resistant K1 strains,
respectively, and the highest SI (638). The authors did also
conduct MOA studies, finding that lead compound 162a could
act on multiple targets, such as binding to heme, P. falciparum
dihydrofolate reductase, and parasite DNA.189b
Similarly, N’Da et al. have recently reported the development
of pyrimidine/4-AQ conjugates, 163−164 (Figure 82), varying
the linker joining the two pharmacophores.190 The most active
hybrid 164 displayed IC50 values of 0.070 and 0.157 μM against
CQ-sensitive (D10) and CQ-resistant (Dd2) strains, com-
parable to those of the parent compounds alone and the
equimolar combination of pyrimethamine with CQ. Addition-
ally, derivative 164 exhibited a high SI (SI = IC50 CHO/IC50
K1) value of 2073.54. The authors found 164 worthy of being
further investigated in order to assess if the antimalarial activity
is retained in in vivo tests; however, no additional results were
reported so far.
Subsequent approaches to dual-action antimalarials bearing
the CQ core included its conjugation with moieties containing
an electrophilic warhead prone to alkylate the cysteine residue
of falcipain, an enzyme that participates in the hemoglobin
degradation process essential for the parasite survival.191 For
instance, Chibale et al. have coupled the core of CQ to the
isatin’s scaffold (165−166, Figure 83), in which the ketone and
thiosemicarbazone moieties could serve as electrophilic war-
heads; hybrids 165−166 were found to display IC50 values for
P. falciparum growth in vitro ranging from 0.051 to 1.51 μM.192
According to the results, the most active compounds were
those with an ethylene linker, and generally, thiosemicarba-
zones were superior to their ketone analogues. However, no
strong correlation between the compound activities against the
parasites and falcipain-2 inhibition was observed, as hybrids
165−166 only exhibited modest IC50 values (>6 μM) against
the cysteine protease. Therefore, these compounds probably
exert their antimalarial activity through a different MOA.
The same authors later reported the synthesis of CQ-based
hybrids 167−168 (Figure 84) by replacing the ketone and
thiosemicarbazone motifs by another electrophilic warhead, the
chalcone moiety.193 The most promising compound 167a
displayed IC50 values ranging from 40 to 90 nM against the
Figure 82. Structure of hybrid compounds 163−164 developed by
N’Da et al.190
Figure 83. Structure of hybrid compounds 165−166 developed by
Chibale et al.192
Figure 84. Structure of hybrid compounds 167−169 developed by
Chibale and co-workers.193
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three tested P. falciparum strains. And, although 167a only
showed activity in the micromolar range against falcipain (IC50
= 10.8 μM), it was highly active as inhibitor of hemozoin
formation, which suggests this could be its primary MOA. In an
effort to improve the solubility of hybrid 167a while its
retaining antimalarial activity, the same group later synthesized
new CQ/chalcone derivatives through replacing the triazole
motif by either an aminoethoxy or piperazine linker.193 The
most active compounds of the series, 169a−b (Figure 84, IC50
of 300−600 nM against P. falciparum D10, Dd2, and W2)
showed improved solubility but did not exhibit better
antimalarial activities than 167a. No cytotoxicity was observed
when compounds 169a−b were tested at a concentration of
100 μM against the Chinese hamster ovarian cell line. The
authors further confirmed that 169a−b also seem to owe their
activity to inhibition of hemozoin formation.193
Following a similar line of thought, Gomes and co-workers
later reported 4-AQ-based hybrids 170 (Figure 85) linking
through a dipeptide spacer the CQ core to a trans-cinnamic
acid motif, capable of inhibiting catalytic Cys residues.194 The
hybrid that best reached the goal to exert antimalarial activity
by inhibiting the two expected targets, i.e. hemozoin formation
conferred by the CQ pharmacophore and P. falciparum cysteine
protease through the electrophilic warhead of the cinnamic
moiety, was 170a. This compound was highly active against β-
hematin formation and displayed IC50 values of 20.3 μM and
3.18 μM against falcipain-2 and CQ-resistant P. falciparum W2,
respectively. Still, the p-iPr derivative 170b, which was unable to
inhibit β-hematin formation and falcipain action, presented the
lowest IC50 of the series against P. falciparum W2 parasite
(IC50= 0.83 μM), suggesting the existence of alternative
mechanism(s) through which these compounds inhibited in
vitro parasite growth. In order to evaluate the influence of the
dipeptide spacer, Gomes and co-workers also synthesized a
series of molecules (171, Figure 85) without any linker
between the quinoline ring and the cinnamic moiety.194 These
compounds were not active against CQ-resistant P. falciparum
W2 at a concentration of 10 μM, showing the relevant role for
the linker joining the 4-AQ and the cinnamoyl moieties in a
single molecule.
Based on these results, Gomes and co-workers then reported
a next generation of compounds with general structure 172
(Figure 86), where a more hydrophobic alkyl spacer replaced
the dipeptide linker.195 These compounds displayed potent in
vitro activity against both blood-stage P. falciparum strains (IC50
= 15.63−137.95 and 11.0−110.8 nM against 3D7 and W2,
respectively) and liver-stage P. berghei (IC50 = 1.06−4.05 μM).
All of them were more active than CQ on both stages, and the
best hybrids, 172a−b (IC50 = 11.0 and 11.6 nM against P.
falciparum W2 strain, respectively), were equipotent to
artemisinin on blood-stage parasites. With the exception of
172c, all the hybrids were also better than PQ on liver-stage
parasites. SAR studies carried out demonstrated that the CQ
core, the butyl linker, and the amide bond between this linker
and the cinnamoyl group were optimal for the dual-stage
activity of the compounds. Furthermore, two of the most
promising compounds (172b,d) were confirmed to be active
against the murine model of malarial infection, although with
modest in vivo performances compared to in vitro ones. This
result could be due to bioavailability issues demanding future
structural optimization of the reported dual-stage leads. As
none of the hybrids 172 presented activity against falcipains
and as the activity presented by the compounds against
hemozoin formation did not fully account for the potent
antimalarial activities observed, Gomes and co-workers are
currently investigating possible MOA underlying dual-stage
activities of hybrids 172.
6. COMPUTATIONAL STUDIES ON ANTIMALARIAL
CLASSICS AND THEIR ANALOGUES
Computational modeling studies have been extremely useful to
elucidate the underlying nature of interactions in many different
chemical and biochemical systems.196 Despite the enormous
successes in several fields, the number of computational-based
studies toward antimalarial drug development is rather low
when compared with the literature arising from the
consideration of experimental techniques. This is essentially
due to the complex life cycle of the malaria parasite and to the
difficulties in the determination of putative receptors and MOA
of compounds with proven antimalarial activity. This picture is
further aggravated by mutations that malaria parasites undergo
to escape antimalarial drugs action. Quite encouraging, the
number of potential targets in the malaria parasite found a
significant increase after the unveiling of the P. falciparum
genome in 2002, which is very beneficial for detailed studies of
the mode of interaction between drugs and receptors of interest
in this field.191a
Most of the computational studies developed so far in the
field of antimalarial chemotherapy concerned hemoglobin
degradation inside parasitized red blood cells, focused either
on inhibition of the parasitic enzymes involved in the globin
Figure 85. Structure of CQ/cinnamic acid hybrid compounds 170−
171 developed by Gomes et al.194
Figure 86. Structure of CQ/cinnamic acid hybrid compounds 172
developed by Gomes et al.195b
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degradation or on the hematin aggregation process.191b The
latter has been traditionally associated with the MOA of
antimalarial 4-AQ, as CQ, whose putative targets have been
investigated for obtaining information on the inhibition
processes at the atomic level. Such knowledge has been often
used to develop quantitative structure−activity relationship
(QSAR) models thought to be useful for the recycling of the 4-
AQ scaffold toward improved antimalarials. Here, relevant
computational approaches can be divided into two large
families, molecular mechanics and ab initio electronic structure
methods, depending on whether classical or quantum
mechanics is used to calculate the interactions between
atoms, groups of atoms, molecules, or even molecular clusters.
The energy of a particular system is calculated as a function of
only the nuclear positions, in the case of the molecular
mechanics (MM) methods, while the nuclear positions and the
electronic structure are considered in the case of the quantum
mechanics (QM) methods. Thus, the choice of one or other
family is usually highly dependent on the size of the molecular
models used to represent the systems of interest and on the
properties to be calculated. The MM methods are computa-
tionally less expensive than the QM methods, but for instance,
they cannot be used to study chemical reactions and to locate
transition state structures or to analyze the electronic charge
distribution in a molecule. The two families of methods include
approaches of different complexity and different degrees of
parametrization, and the rule of thumb for practical applications
is the larger the system, the more approximate the approach.
Among the vast computational modeling machinery,
molecular docking is employed to predict the preferred
orientations of molecules (drugs) around macromolecular
receptors based on a score function to discriminate and rank
the stability of a very large number of possible binding poses.
The most sophisticated docking algorithms can tackle flexible
systems and simulate the solvent effects. Thus, if the structure
of a putative drug receptor is known, docking methods can be
used for structural elucidation or for virtual high throughput
screening (vHTS) purposes, i.e., for screening compound
libraries in order to rank their abilities to bind the target
receptor. The ligand−receptor structures obtained with
molecular docking can be further refined by MM, by QM, or
by a combination of both approaches (QM/MM). In the latter,
QM is used to model the region of contact while MM is used
for the remaining system and to provide a correct embedding of
the QM region, i.e., to mimic the full system and the effects of
the solvent. The most used QM methods are based on the
density functional theory (DFT), which relies on the
calculation of the energy of the system from the electron
density through an appropriate density functional. This is due
to the fact that, for an N-electron system, the computational
efforts in the case of DFT methods scale with N3 while wave
function based methods scale with N4 (or even more). The
computational burden may be alleviated by the consideration of
additional approximations and of empirical parameters giving
rise to the semiempirical approaches. Both for QM and MM
methods, it is possible to calculate the time dependent behavior
of a molecular system, in the so-called molecular dynamics
(MD) simulations. For additional details, the interested reader
may consult textbooks on the subject of computational
chemistry.197
6.1. Targeting Inhibition of Hemozoin Formation
Some of the computational approaches introduced above were
used by Portela et al. to investigate the interaction of several 4-
AQ antimalarials, including AMQ and CQ, with two putative
targets involved in the hematin aggregation process, namely,
the μ-oxo-dimer of hematin and the hemozoin dimer (Figure
87).198 Their main idea was to obtain further knowledge about
the molecular mechanisms underlying the antimalarial action of
4-AQ, which is very relevant both for the synthesis of new
compounds and for the chemical recycling, i.e., structural
optimization of existing antimalarials. Due to the absence of an
experimental structure for the μ-oxo-dimer of hematin, Portela
et al. used primarily a classical approach (CHARMM force
field) for a conformational search of the most likely position of
the porphyrin subunits, which was followed by an optimization
of the structure with the AM1(d) semiempirical method.199 In
turn, the structure of the hemozoin dimer used was that
reported by Pagola and co-workers.200 The optimized and
crystallographic structures of the μ-oxo-dimer of hematin and
of the hemozoin dimer (Figure 87), respectively, were
considered in subsequent single-point calculations with the
B3LYP functional (a popular DFT-based hybrid approach) for
calculation of the electrostatic properties.201 In the case of the
former species, the molecular electrostatic potential (MEP)
surface shows the concentration of the negative potential at the
iron atom, the tetrapyrrole system and, to a smaller extent, at
the carboxyl oxygen atoms, while the positive potential is at the
other regions.198 The hemozoin dimer shows negative potential
at the iron-carboxylate region and positive potential in the
Figure 87. Molecular models of the μ-oxo-dimer of hematin (left) and of the hemozoin dimer (right). Reprinted with permission of the Federation
of the European Biochemical Societies from ref 198. Copyright 2003 Elsevier.
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peripheral molecular volume. The concentration of negative
potential at the central region of the two putative targets
surrounded by a region of positive potential suggests that the
antimalarial activity would be enhanced for compounds
presenting a region with positive potential surrounded by a
region of negative potential; that is, the compounds should
present an electrostatic potential profile complementary to
those found for the targets.
Curiously, the calculations performed by Portela et al. show
that the electrostatic profiles of several inhibitors of hematin
aggregation, e.g. AMQ, CQ, Q, and derivatives, are in
agreement with the complementarity-based hypothesis of
drug/receptor association. Further docking studies show that
the association of 4-AQ with the deprotonated form of hematin
μ-oxo-dimer occurs through contacts of the amino group at the
quinoline’s C-4 and the central region of the hematin dimer
and also of the negative potential aromatic regions of the ligand
and the peripheral positive regions of the receptor (Figure 88).
In the case of the hemozoin target, the association of 4-AQ
occurred also between the negative area at the iron-carboxylate
moiety and the area of positive potential of the ligands.198
Rafiee et al. analyzed the relationship between the electronic
structures of several aminoquinolines (AQ, Figure 89) and their
ability to interact with hematin.202 Such analyses were based on
calculated data for the nuclear quadrupole coupling constants
(NQCC) obtained from the components of the electric field
gradient (EFG) tensor in the principal axis system calculated at
the B3LYP/6-31G* level of theory. The NQCC for 14N in the
quinoline rings of 3-, 5-, 6-, and 8-AQ substantially differ from
those of 2- and 4-AQ; that is, the NQCC for 14N in the latter
compounds are larger than in the former. In other words, the
charge density on the nitrogen from the quinoline ring is larger
for 2- and 4-AQ than for the other AQ considered, which is in
agreement both with the fact that 8-AQ, like PQ, does not owe
its antimalarial action to inhibition of hemozoin formation203
and with observation of stronger complexes with hematin in
aqueous dimethyl sulfoxide (DMSO) solution in the former
than in the latter AQ.140c,204 Additionally, Rafiee et al.
compared the variation of the NQCC in the 14N and 2H
nuclei of isolated 2- and 4-AQ and of their complexes with
Fe(III) and concluded that the change of charge density on
nitrogen is greater than that of deuteriums, which suggests that
binding to hematin is indeed related with the charge density in
the nitrogen atom of the quinoline ring.202 But, as presented
below, the relationship between charge density profiles at the
quinoline ring, the binding to hematin, and the inhibition of β-
hematin formation is not that simple.
Nsumiwa et al. calculated, also at the B3LYP level of theory,
Mulliken and CHelpG atomic charges for neutral and
quinolinium forms of several 7-substituted 4-AQ (Figure 90),
in vacuum or under implicit water solvent conditions, which
were correlated with either the logarithm of the constant of
association to hematin (logK) measured in aqueous DMSO,
the logarithm of the 50% β-hematin inhibitory activity
(logBHIA50), or both.
205 The experimental data were also
correlated with empirical properties, such as the hydrophobicity
and substituent Hammett constants, which suggested that the
inhibition of β-hematin formation appears to be favored by
Figure 88. Electrostatic potential isosurfaces for chloroquine (left) and amodiaquine (right). Negative and positive potential regions are shown in
blue and white, respectively. Reprinted with permission of the Federation of the European Biochemical Societies from ref 198. Copyright 2003
Elsevier.
Figure 89. Structures of the AQ considered for the calculations of the
NQCC by Rafiee et al.202
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stronger association with ferriprotoporphyrin IX (hematin) and
by more electron withdrawing substituents at position 7 of the
quinoline ring. In the case of the charges calculated with the
Mulliken approximation for the R = H series (Figure 90), eight
statistically significant (P < 0.05) correlations of logK and single
atomic charges were found and two additional correlations were
obtained from multiple linear correlation analysis (MLCA).
The best correlation was found between logK and the charges
on carbon atoms 6 and 8a (cf. Figure 90) for the neutral forms
in water.205c The association is predicted to be favored by
greater negative charge at C8a and reduced negative charge at
C6, but in the case of the other series, the logK values estimated
with the relationship obtained for the R = H series were found
not to correlate with the experimental results.205c Many
correlations were found between the logBHIA50 and Mulliken
atomic charges, but the strongest one was based on the charges
at the N1 and H8 atoms of the quinolinium forms, with
increased activity favored by a less negative charge on N1 and a
more positive charge on H8.205c
In the case of the CHelpG charges, the strongest correlation
with the logK for compounds with R = H was obtained for the
quinolinium species in vacuum and involved atoms X and H8,
with the association with hematin favored by a more negative
charge on X (withdrawing groups are benefic) and a less
positive change on H8. Interestingly, by contrast to the results
obtained with the Mulliken charges, logK values calculated for
the other series with the relationship derived for R = H based
on the CHelpG charges produced a statistically significant
linear correlation with the experimental logK values.205c In the
case of logBHIA50, the results from Nsumiwa et al. suggest that
the charges in the N1 and C8 or N1 and C7 (neutral species in
vacuum) provided very good correlations and that the β-
hematin inhibitory activity is improved with decreasing negative
charge on N1, decreasing negative charge on C8, and
decreasing positive charge on C7.205c Notice that a comparative
analysis is difficult, since correlations obtained for logK and for
logBHIA50 based on Mulliken or CHelpG charges involve
different species, namely, quinolinium and neutral forms, in
vacuum or in implicit solvent.205c
In summary, the correlations based on Mulliken and CHelpG
atomic charges as introduced by Nsumiwa et al. show that the
quinoline ring is key for the inhibition of β-hematin formation
and that withdrawing groups (NO2, CN, Cl and CF3) at
position 7 are crucial.205c Analogues with electron donating
groups at position 7 were found to be poor inhibitors of β-
hematin formation. Importantly, it was found that specific
atoms yielding statistically meaningful correlations for logK are
for the most part not the same as those that yield interesting
correlations for logBHIA50. In the case of the R = H series, no
experimental correlation was found between logK and
logBHIA50, which suggests that inhibition of β-hematin
formation is not directly related to the association between 4-
AQ and ferriprotoporphyrin IX in solution. Thus, inhibition of
β-hematin formation seems to occur preferentially by
interaction of the inhibitor with the growing crystal surface,
but since some correlation was found between logK and
logBHIA50 as the lateral side chain is lengthened, a role for
solution association cannot be ruled out for all 4-AQ.205c Quite
interestingly, Nsumiwa et al. suggest that the extension of the
lateral side-chain, despite not having a visible effect on β-
hematin inhibition, modulates the influence of the substituent
at position 7 in the quinoline ring.205c
In another combined experimental and computational study,
Dubar et al. docked the interaction of FQ (cf. Figure 44) with a
synthetic hemozoin crystal (β-hematin), and found that the
ligand can interact specifically with the {0,0,1} and {1,0,0} faces
of hemozoin, blocking crystal growth.200,206 Notably, inter-
calation of the quinoline rings between the heme rings in the
{0,0,1} face of hemozoin was found, along with the formation
of hydrogen bonds with the heme surface, while the formation
of N−H···O contacts between deprotonated FQ and charged
carboxylate groups of hemozoin was important when the
interaction occurs with the {1,0,0} face of the crystal.206 These
findings agree well with previous results obtained by Buller et
al. for the interaction of 4-AQ (4-amino-7-chloroquinoline, CQ,
4-hydroxyanilino-7-chloroquinoline, and AMQ) and PQ with
synthetic β-hematin.200,207 The docked configurations in the
work of Buller et al. show that CQ and AMQ stereochemically
cap onto the {0,0,1} face of the β-hematin crystal via
(porphyrin)acid−(quinoline)amine salt bridges and by inter-
calation of the quinoline rings between the aromatic groups of
the crystal. Additionally, these two compounds form
(aromatic)N···HCC(vinyl) and CCl···H3C interactions
which aid the host to anchor the guest within the crevice.207
While the formation of the salt bridge and ring intercalation are
still possible in the case of PQ, the latter hydrogen interactions
are not possible in the case of this 8-AQ. This is one of the
reasons for the lower drug−hematin binding energy of PQ as
compared with CQ and AMQ, which agrees with the fact that
PQ is known as a poor hemozoin growth inhibitor. Notably,
quinoline drugs would not be able to dock effectively into
position at the {0,0,1} face when protonated at the aromatic
nitrogen (N1) atom.207
Dubar et al. also compared the influence of the structures of
FQ, and other metallo-4-AQ, namely, ruthenoquine (RQ),
methylferroquine (Me-FQ), and methylruthenoquine (Me-
RQ) (Figure 91) on properties considered to be relevant for
antimalarial activity, namely, lipophilicity, heme binding, and
noncovalent interactions with hemozoin.206
Figure 90. General chemical structures of the four different series of 7-
X-4-AQ studied by Nsumiwa et al.205c
Figure 91. Chemical structures of (a) metallo-CQ derivatives FQ and
RQ, and (b) N-methylmetallo-CQ derivatives Me-FQ and Me-RQ.
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The methylated derivatives were considered since a possible
explanation for the enhanced activity of FQ when compared
with that of CQ is that its folded conformation through the
establishment of an intramolecular hydrogen bond (Figure 92)
improves its lipophilic character, which, expectedly, enhances
its membrane permeation. The formation of the intramolecular
hydrogen bond is hindered in the methylated compounds.
Dubar et al. considered the RPBE approach (another DFT
functional) and the TZVP basis set to optimize the structures
of the FQ, RQ, and their methylated congeners in
vacuum.206,208 They found that the optimal structures of FQ
and RQ (Figure 92) present intramolecular hydrogen bonds
between the unprotonated terminal tertiary amino group and
the 4-amino group of the quinoline ring; the bond in FQ was
calculated to be 1.4 kcal·mol−1 stronger than in RQ. The polar
surface areas estimated from the MEP surfaces for FQ and Me-
FQ, with values 14 Å2 and 10 Å2, respectively, suggest that, at
least in low dielectric media, the nonmethylated derivatives are
likely to exhibit an intramolecular hydrogen bond. Experimental
nuclear magnetic resonance (NMR) studies for the compounds
in CDCl3 demonstrate the existence of such intramolecular
bonds and folded configurations for FQ and RQ, but also in
CQ, and their absence in Me-FQ and Me-RQ. In the case of
water solvent, combined computational studies and NMR
experiments show that intramolecular hydrogen bonds in the
lateral side chains of FQ and RQ compounds are not formed,
which suggests that the hydrogen bonds are susceptible to the
dielectricity of the medium. This is very relevant for the
crossing of membranes, as the observation of a subtle balance
between neutral, monoprotonated, and deprotonated forms of
the FQ and RQ compounds is equally important.206 The
methylation of the 4-amino group of FQ and RQ was found to
reduce their biological activities but also their toxicity by almost
an order of magnitude.206 The ability of FQ, RQ, and their
methylated derivatives to generate hydroxyl radicals was also
evaluated from a combination of experimental and computa-
tional approaches. Calculations were very relevant in this
respect for compounds with ruthenium, since cyclic voltam-
metry experiments were not possible due to electroprecipita-
tion issues. It was suggested that FQ and Me-FQ can generate
hydroxyl radicals while such is not possible with their
ruthenium counterparts. These results probably explain why
only FQ and Me-FQ break down the parasite’s FV
membrane.206
In another study reviving the 4-AQ pharmacophore, Aguiar
et al. used experimental and computational techniques to
examine the antimalarial activity and mechanisms of action of
compounds 173 and 174 (Figure 93) against CQ-resistant
parasites.149a These compounds were tested against P.
falciparum in vitro and against P. berghei in mice, and they
were also evaluated in vitro for their cytotoxicity and ability to
inhibit hemozoin formation. 173, 174, and CQ showed activity
in the nanomolar range against CQ-resistant/mefloquine-
sensitive (W2) and CQ-sensitive (3D7) P. falciparum parasites,
Figure 92. Optimized structure for FQ obtained at the RPBE/TZVP level of theory.206 The internal hydrogen bond is highlighted by a dotted line
and has a length of 2.229 Å. In the similar RQ compound, the length of the intramolecular hydrogen bond is 2.236 Å.
Figure 93. Structures of compounds 173 and 174.
Chemical Reviews Review
dx.doi.org/10.1021/cr500123g | Chem. Rev. 2014, 114, 11164−1122011201
and they were also found to be active when evaluated in mice.
Additionally, 173 and 174 did not display toxicity against
human hepatoma (HepG2) or kidney (BGM) cell lines. The
two novel compounds inhibit heme polymerization, and
docking studies, in the presence of water and considering
molecular flexibility, show that they interact with dimeric
hematin in similar fashion to CQ. In the highest ranked
conformations, the aromatic rings of all protonated forms of
173 and 174 are parallel to the ferriprotoporphyrin group, and
the interaction also involves weak hydrogen bonding, as
happens with CQ. The presence of two quinoline moieties in
174 was found to increase the probability of hydrophobic
interactions when compared with the compound with just a
quinoline ring. In fact, the docking energies for the protonated
forms of 174 were found to be larger (more negative) than
those corresponding to the CQ and 173 compounds. In order
to analyze if 173 and 174 were NADH competitors, Aguiar et
al. also docked these compounds to P. falciparum L-lactate
dehydrogenase (PfLDH). The model for PfLDH was obtained
from a 3D structure of PfLDH complexed with NADH and the
oxamate substrate available at the Protein Data Bank (PDB,
code 1LDG).209 From the calculated interaction energies, 173
and 174 are suggested to be weak inhibitors of PfLDH, as
happens with CQ.149a Nevertheless, as found in docking studies
to dimeric hematin, the interaction of protonated forms of 174
with PfLDH is energetically more favorable than protonated
forms of CQ and 173, which suggests that the 174 scaffold can
be a very interesting target for additional synthetic
modifications.
6.2. Aiming at Inhibition of Other Parasitic Targets
Singh et al. combined the best of two worlds in a series of
hybrid compounds (162, Figure 81 in section 5.2.5) featuring
the 4-amino-7-chloroquinoline moiety, due to the character-
istics associated with this molecular entity in blocking heme
polymerization, and the 2-aminopyrimidine moiety, due to the
role of 2,4-diaminopyrimidine drugs in the inhibition of P.
falciparum dihydrofolate reductase (PfDHFR).189b These
authors considered molecular docking for understanding
whether the antiplasmodial activity of the synthesized
compounds could or not be attributed to inhibition of
PfDHFR. They considered the PDB structure of wild-type P.
falciparum DHFR-thymidylate synthase (PfDHFR-TS) com-
plexed with WR99210 (lead compound shown in Figure 94),
NADPH, and dUMP with code 1J3I. Close inspection of the
top scored configurations for compound 162a (Figure 81 in
section 5.2.5) and WR99210 shows that the former adopts a
slightly different pose when compared to the latter.
Importantly, 162a was found to establish more hydrogen
contacts with PfDHFR than WR99210, which originated a
better top score for the former compound. Such improved
interaction seems to be the relevant factor for the significant
antiplasmodial activity evidenced by 162a.189b Very recently,
Bhat et al. docked a series of 4-AQ-1,3,5-triazines with P.
falciparum DHFR to correlate activity and specific interactions
between the ligands and residues of wild type (PDB code: 1J3I)
and quadruple mutant (PDB code: 3QG2) PfDHFR.210
Despite identification of the contacts made by each compound
with PfDHFR, which can be relevant for future synthetic
studies, unfortunately, a clear correlation between antimalarial
potency and the strength of the interaction was not established.
In a similar approach to that of Singh et al., Gomes and co-
workers reported in the same year and journal a series of novel
compounds based on the CQ core and on the cinnamoyl
moiety, linked to each other either directly or through a retro-
enantio dipeptide spacer (170−171, Figure 85 in section
5.2.5).189b,194 As already mentioned in the previous section, it
was found that the compounds with the dipeptide spacer (170)
inhibited in vitro both hemozoin formation and development of
blood-stage P. falciparum, while compounds without the spacer
(171) were better falcipain-2 (FP2) inhibitors; none of the
compounds was a falcipain-3 (FP3) inhibitor. In order to obtain
additional knowledge about the FP2 inhibitory capacity of the
latter compounds, molecular docking and MD simulations were
performed to predict the structures of the complexes between
the compounds with or without the dipeptide linker and FP2
(PDB code: 3BPF) or FP3 (PDB code: 3BWK). The
calculations suggest that both families of compounds cannot
fit into the catalytic site of FP3 as efficiently as into that of FP2.
In fact, the docked configurations for the most active inhibitor
with the dipeptide linker (170 with R = H) show that its vinyl
group is located in the S2 subsite of FP2 but with the vinyl
bond at ∼4.5 Å of the enzyme’s Cys thiolate (A), while in FP3
it appears at the S2′ well (Figure 95B). In the case of the most
active compound without the dipeptide spacer (171 with R =
m-NO2), the vinyl group is also located in the S2 subsite of FP2
with the vinyl bond at ∼3 Å of the enzyme’s Cys thiolate
(Figure 95C), but in the case of FP3 the compound is outside
the binding pocket (Figure 95D). All compounds with and
without the spacer were found to not fit entirely in the binding
pocket of FP3, which seems to be a convincing explanation for
their lack of FP3 inhibitory activity. In the case of FP2, the
shorter distance between the vinyl bond of the compounds
without the linker and the Cys thiolate of the enzyme than for
the compounds with the spacer is in line with the experimental
observation that the former were better FP2 inhibitors.194
While molecular docking combined with realistic molecular
models is able to provide static information about the most
favorable host−guest configurations, MD simulations can be
used to gain knowledge on the evolution of the docked
configurations with time. In fact, Gomes and co-workers
showed that FP2 inhibitory activities measured experimentally
could be correlated with the time evolution of the distance
between the vinyl bond and the enzyme’s Cys thiolate
determined from classical MD simulation. It was found that
compounds manifesting FP2 inhibitory activity kept their vinyl
bond within 3.5−4 Å of the thiolate, while the distance
increased to larger values in those compounds shown to be
weak FP2 inhibitors. Note that this information is based just on
the noncovalent interactions since the electronic structure is
not taken into account in the classical approaches considered
by those authors.194 Nevertheless, this strategy was proven to
be quite robust again in a separate study where the same
authors synthesized a novel family of cinnamic acid/
chloroquinoline conjugates but linked by an alkyl spacer
group (172, Figure 86 in section 5.2.5).195a The latter
compounds were found to be more active (nanomolar range,
in vitro assays) against CQ-resistant P. falciparum W2 strain
Figure 94. Chemical structure of lead compound WR99210.
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than those without spacer (171) or those with a dipeptide
linker (170). Experimental in vitro data suggest that their
potent antiplasmodial activity was not exerted through FP2
inhibition. Such experimental findings were corroborated with
results from MD simulations on the docked configurations
showing that the putative site of nucleophilic attack, i.e., the
vinyl group, also moves away from the enzyme’s Cys thiolate in
the compounds with the alkyl linker (172).195a
Acridine-inspired derivatives have also been the focus of
computational studies, as their mechanisms of antimalarial
action remain unclear. Biagini et al. investigated by
experimental and computational approaches the MOA of two
dihydroacridinediones, namely, compounds 52 and 58 (cf.
Figures 26 and 27, respectively), shown to have antimalarial
activity.90b Thermodynamic analysis of heme-binding showed
that both compounds could bind to heme but to a lesser extent
than CQ and AMQ (CQ > AMQ > 52 ≫ 58). The low heme
binding affinity of floxacrine (52), IC50 = 140 nM, is in line
with its lower in vitro antimalarial activity when compared with
CQ and AMQ with IC50s of 7.4 nM and 4.5 nM, respectively.
However, IC50 of 15 nM for 58 contrasts with its very poor
affinity for heme, and therefore, the MOA of dihydroacridine-
diones cannot be explained by interaction with heme. Hence,
the ability of the dihydroacridinediones to inhibit bc1 complex
activity was compared with those of known inhibitors
atovaquone, sitgmatellin and myxothiazol. Compound 58 was
shown to inhibit selectively and exclusively P. falciparum bc1
complex with IC50 = 3 nM and Ki = 0.3 nM, values identical to
those for atovaquone but with the latter having superior
selectivity (much smaller IC50s for bc1 complex inhibition in
bovine heart, rat liver and human liver than those of 58).
Compound 52 displayed moderate inhibitory activity against
cross-species bc1 activities but without selectivity for P.
falciparum bc1. Further experiments with wild-type yeast and
mutants showed that these compounds target the Qo site of the
bc1 complex. For better understanding the inhibitory process,
Biagini et al. constructed a homology model of the P. falciparum
cytochrome b using as structural template the atomic
coordinates from its bovine counterpart (Figure 96), which
was used to dock compounds 52 and 58.90b
These compounds were found to bind favorably the P.
falciparum bc1 model. Compound 58 was within 4 Å of Qo site
residues with ligand−host interactions predominantly hydro-
phobic, but a backbone hydrogen bond from Ser241 to the
Figure 95. Preferred docked binding mode of the most active cinnamic acid/chloroquinoline conjugates with (top) and without (bottom) a
dipeptide linker into FP2 (left) and FP3 (right) binding sites. The inhibitors are shown in ball and stick representation while residues forming the
“oxyanion hole” of parasitic cysteine proteases are in CPK representation. Reproduced with permission from ref 194. Copyright 2012 Elsevier
Masson SAS. All rights reserved.
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aromatic secondary amine of the ligand was also seen (Figure
97).
Importantly, a putative association between the inhibitor and
residues 236−241 constituting the E-ef linker region of the
cytochrome was observed; this region possesses low sequence
identity between P. falciparum and mammalian cytochrome b.
Despite the absence of water molecules in the Qo site of the
model, with possible influence in the binding energy and pose
obtained by molecular docking, the computational results
explain the very high selectivity of compound 58 highlighted
above, which is very encouraging for other investigations in the
field.
6.3. Investigating Possible Mechanisms of Drug Toxicity
Another relevant piece of information that may be obtained
from the consideration of computational approaches regards
the understanding of biochemical processes associated with
drug toxicity. An example of such an approach is the work of
Liu et al. focused on the possible molecular mechanism
underlying methemoglobinemia caused by 8-AQ, particularly in
G6PD-deficient patients.211 These authors hypothesized that, in
the process of converting O2 to H2O2, one electron is provided
by oxidation of the Fe(II) from hemoglobin, which is
concomitantly converted into methemoglobin, and the second
electron comes from an 8-AQ metabolite.211 PQ metabolites
considered were 5-hydroxy-PQ, 6-methoxy-8-AQ, and carboxy-
PQ, respectively, structures 16, 17, and 18 in Figure 8, section
3.2. While PQ requires metabolic activation before leading to
the formation of methemoglobin, 5-hydroxy-PQ (16) is known
to cause methemoglobinemia and to form H2O2 and hence was
chosen to test their working hypothesis. As in the studies
reviewed above (section 6.1), due to pH conditions, the
protonated 8-aminoalkylammonium form of 16 was considered
for the calculations. The structure of hemoglobin was taken
from the crystal structure of horse carbonmonoxyhemoglobin
complexed with 2-[4-(3,5-dichlorophenylureido)phenoxy]-2-
methylpropionic acid, with PDB code 2D5X. Molecular
docking shows that compound 16 interacts with the carboxylic
side chain of heme through the terminal ammonium group.211
The pose derived in the previous step was used as input for the
DFT calculations (B3LYP approach considering an unrestricted
formalism) in which the structures of unprotonated, singly
protonated, and doubly protonated forms of O2···hemoglobin···
16 complexes were fully optimized. It was found for all
protonation states that a proton is transferred from the terminal
ammonium group to the carboxylic group of heme, resulting in
a −H2N···HOOC− local configuration. In the case of the
unprotonated complex, and for all possible spin states, a single
electron is transferred to O2 and, since the spin density in
compound 16 is zero, it is contributed by Fe(II) forming a local
Fe(III)···O2
•− moiety. In the case of the single-protonated
complex, it is found for different states that ∼0.6 electrons are
contributed by 16. In the case of the double protonated
complex, the 16 species presents a spin density around 1.0,
which confirms the hypothesis that the second electron
transferred to the π* orbital of O2 comes from 16.
211 Liu et
al. end by suggesting that the mechanism unveiled by the DFT
calculations may be generalized to other aromatic compounds
that interact with the carboxyl arm of heme via hydrogen
bonding either through amine or hydroxyl groups. This
suggestion is supported by the observation that aniline and
its metabolites catalyze the production of methemoglobin in
vivo.
The studies reviewed above demonstrate that important
atomic level information on the role of drugs and their
interaction mechanisms on defined targets can be obtained at
low cost by the consideration of computational chemistry
techniques. The quality of the results will be dramatically
improved if electronic structure methods and more realistic
models are used, which has to be envisaged in the near future
due to significant progresses in the field (e.g., computer
architectures, computational algorithms, and theories) and to
the unveiling of targets important to the life cycle of the malaria
parasite. Moreover, computational methods are crucial in the
screening of bioactive compound libraries aimed at rescuing or
repurposing (see next section) known structures to the field of
malaria chemotherapy. In summary, no less than a bright future
is to be expected for application of computational methods to
the search for new antimalarial agents.
Figure 96. Structural alignment of selected regions from the Qo site
regions of the bovine (red, PDB code: 1SQX) and of the P. falciparum
homology model (green) cytochrome b complexes. Relevant residues,
including the catalytically essential PEWY motif, are highlighted.
Adapted with permission from ref 90b. Copyright 2008 American
Society for Pharmacology and Experimental Therapeutics.
Figure 97. Compound 58 (white cylinders) docked at the Qo site of
the P. falciparum homology model of cytochrome b. Only cytochrome
b residues within 4 Å of the inhibitor are shown (CPK). Adapted with
permission from ref 90b. Copyright 2008 American Society for
Pharmacology and Experimental Therapeutics.
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7. RESCUING AND REPURPOSING DRUGS FOR
MALARIA
As shown by previous sections, one main approach to
accelerate the development of novel antimalarials is to start
from the chemical framework of known ones to produce new
drugs. However, as developing new drug products is a costly
and time-consuming process, a cost-effective reduced-risk
strategy is to identify new therapeutic uses for molecules that
were already synthesized but did not find clinical application
(rescuing) or that were already approved to treat a specific
disease or group of diseases but might be relevant against other
therapeutic targets (repurposing). The basis for drug rescuing/
repurposing (r&r) relies on the fact that many drug targets are
eventually shared by more than one physiological process. Such
a paradigm shift is enhanced by the increasing awareness that
many drugs may have more than one biological target.212 This
drug “promiscuity” has motivated several groups to pursue drug
r&r with promising results.212b,213 In addition, the high costs
and failure rates to bring drugs to market have led to more and
more interest in drug r&r.214
Drug r&r is primarily driven by serendipitous observations in
clinical and preclinical in vivo settings, of which the high profile
drug sildenafil by Pfizer, first developed for angina but later
approved for erectile dysfunction, is an emblematic example.215
Another classic example is thalidomide by Celgene, first
marketed for morning sickness, and then approved for leprosy
and recently for multiple myeloma.216 Genomic screens have
also contributed to find new uses for known drugs. For
example, the antileishmanial properties of amphotericin,
originally developed to treat fungal infections by disrupting
the pathogen’s plasma membrane through binding to sterols,
were identified based on the discovery of homologous 24-
substituted sterols in leishmanial cells.217 Rescued/repurposed
drugs have also been discovered through cell-based screenings
directly against living organisms, which has been the major
thrust area for the chemotherapy of tropical parasitic diseases.
The undeniable advantages of drug r&r are particularly valuable
for development of medicines against diseases endemic to low-
income countries, such as malaria.218
Drug r&r in malaria is not as novel as one might think. The
sulfur-based antibacterial drugs developed as dyes in the early
1900s are a classical example of compounds that were rescued/
repurposed to treat malaria and to serve as starting points to
develop new active compounds. Examples are sulfonamide
drugs such as sulfadiazine and sulfanilamide, as well as the
sulfone dapsone, which were a landmark of early synthetic
antibacterial agents later found to exhibit antimalarial proper-
ties.219 Dapsone’s relevance as an antimalarial was established
in the 1940s, but the efficacy of the already in use quinine
outshined these findings; it was only during the Vietnam War
that the interest to pursue the development of dapsone as an
antimalarial was renewed.220 This interest was further
confirmed when it was demonstrated that dapsone synergized
with inhibitors of dihydrofolate reductase, which led to the
development of Lapdap (a combination of dapsone and
chlorproguanil) by a public−private partnership between the
WHO, the British Government, the University of Liverpool,
and GlaxoSmithKline.221 Clinical trials of Lapdap were
performed in Africa and, although more cases of anemia
appeared in patients treated with dapsone−chlorproguanil, the
drug was licensed in the U.K. in 2003.222 Unfortunately,
GlaxoSmithKline withdrew Lapdap in 2008 due to significant
reductions in hemoglobin levels of G6PD-deficient patients.222b
As dapsone causes hemolytic anemia, this potential side effect
was to be expected; still, no link between Lapdap, anemia
aggravation, and G6PD deficiency was observed because no
G6PD testing was done during a key study.222b The dapsone
example highlights how drug repurposing can be derailed by
predictable side effects. Thus, although drug r&r is a cost-
effective reduced-risk strategy, it is important to bear in mind
that clinical trials to detect known complications of existing
drugs are needed in order to ensure safety.
In the dawn of the 21st century, several groups at
pharmaceutical companies and academic institutions have
performed cell-based screens of their chemical libraries,
containing approved, discontinued and/or “shelved” drugs,
against tropical parasitic diseases. For example, Chong, Sullivan
and co-workers have created a library of 2,687 existing drugs,
called the Johns Hopkins Clinical Compound Library
(JHCCL), and have screened it for inhibition of P. falciparum
growth.187 The nonsedating antihistamine astemizole (175,
Figure 98) was one of the most promising compounds
identified, by inhibiting both CQ-sensitive (3D7) and CQ-
resistant (Dd2) P. falciparum strains with IC50 values of 227 and
457 nM, respectively. Remarkably, desmethylastemizole (176,
Figure 98), the principal human metabolite of astemizole, was
approximately two to four times more potent than its parent
compound, having IC50 = 117 nM or 106 nM against 3D7 or
Dd2 P. falciparum strains, respectively.187 The two compounds
showed efficacy in P. vinkey-infected mice, reducing parasitemia
by 80 and 81% when treated with astemizole (intraperitoneal
daily dose of 30 mg/m2 for 4 days) and desmethylastemizole
(intraperitoneal daily dose of 15 mg/m2 for 4 days),
respectively.187 The same researchers also determined that
these two compounds concentrate inside the parasite’s FV and,
like antimalarial 4-AQ, inhibit heme crystallization.187 Although
astemizole and its main metabolite did not present enough
potency as to immediately enter clinical trials, their scaffold is a
starting point for further development. As a long-term goal, the
JHCCL initiative is intended to add to its collection the
approximately 11,000 drugs ever used in medicine, aiming at
their rescuing/repurposing, and to make such a set available to
Figure 98. Structures of astemizole (175) and desmethylastemizole
(176).
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any researcher willing to screen it for rare and/or neglected
diseases.
A few years later, a similar but even more ambitious
screening project took place.223 Since 2008, nearly six million
molecules have been screened against blood-stage P. falciparum
parasites.224 This generated a plethora of hits, approximately
0.5% of which presented an EC50 below 1 μM, hence serving as
promising leads for candidates with novel mechanisms of
antimalarial action.223 The pharmaceutical companies involved
in this campaign, Novartis and GlaxoSmithKline, and the St.
Jude Children’s Research Hospital, have made the most of
these drug discovery data, including chemical structures, freely
available and fully searchable through the European Bio-
informatics Institute’s ChEMBL database.225 Among the active
compounds identified through this screening campaign, a
molecule belonging to the spiroazepineindole family (177,
Figure 99) entered into the lead optimization phase due to its
potent antimalarial activity and favorable pharmacological
profile.226 This project was developed by the NGBS
consortium, a collaboration between the Novartis Institute for
Tropical Diseases, the Genomic Institute of the Novartis
Research Foundation, The Biomedical Primates Research
Center, and the Swiss Tropical Institute.227 After evaluation
of approximately 200 analogues, the optimized spiroindolone
NITD609 (178, Figure 99) was obtained.226 This compound is
a potent antimalarial candidate that (i) kills the blood stages of
P. falciparum (IC50 = 0.7 and 0.9 nM for 3D7 and W2 strains,
respectively) and P. vivax (IC50 < 10 nM) by rapidly inhibiting
a parasite’s protein biosynthesis and (ii) presents a single oral
dose cure at 100 mg/kg in the P. berghei mouse model.226 In
the same study, results from NITD609’s target identification
efforts, through drug pressure to a cultured clone of P.
falciparum Dd2, suggested this compound might act on the P-
type cation-transporter ATPase 4.226 Later, it was also found
that NITD609 (i) inhibits the early and late development of P.
falciparum gametocytes in a dose-dependent manner (5−500
nM) and (ii) is very effective in decreasing transmission to the
Anopheles stephensi mosquito vector.228 Five years after the
screening campaign, NITD609 entered phase IIa clinical studies
in 2012, representing a remarkable achievement for a new class
of molecules and reinforcing the tremendous potential of drug
rescuing and/or repurposing.227
Similar screens have been performed leading to other
molecules that have entered into lead optimization develop-
ment, as was recently reviewed by two papers on the
subject.136b,229 For the sake of simplicity, the remainder of
this section will mainly focus on compounds belonging to two
major drug families, antitumorals and antiretrovirals, which
have been rescued and/or repurposed for malaria since 2000
and reported as displaying potent antiparasitic activity.
7.1. Antitumorals
Several intracellular pathogens ensure survival by tailoring their
host environment to their specific need through interference
with cellular programs such as cell proliferation, differentiation
and death.230 These findings led to the exploration of
antitumoral drugs toward antimalarial drug development, an
approach that has been further enhanced by the recent
discovery that artesunate is effective against some cancer
types.231 In a recent study, two antitumoral compounds, Bay
43-9006 and SU-11274 (179 and 180 respectively, Figure 100),
were shown to present potent activities against the P. falciparum
W2 strain with IC50’s of 384 and 320 nM, respectively.
232 In
humans, the known targets responsible for the antitumoral
properties of Bay 43-9006 are the serine−threonine kinase B-
Raf, the Raf/MEK/Erk pathway, and several receptor tyrosine
kinases.233 However, no homologous MEK/Erk kinase cascade
was observed nor have tyrosine kinases been identified in
malaria parasites. Still, the potent antimalarial activity of this
compound should motivate researchers to further screen Bay
43-9006 derivatives and analogues as parasite growth
inhibitors.234 SU-11274 was designed as an antitumoral that
acts as a human ATP competitive inhibitor of the MET
receptor tyrosine kinase activity.235 Recently, it was shown that
the inhibition of the hepatocyte growth factor/MET kinase
(HFG/MET) signaling pathway leads to an increase in
apoptosis of P. falciparum-infected cells, consequently inducing
a considerable reduction of infection.236 However, it was not
confirmed that this could be the possible target for SU-11274
activity against P. falciparum. Although the specific mechanisms
of SU-11274 and Bay 43-9006 antimalarial action remain
unclear, the Plasmodium kinome, which is emerging as a major
antimalarial strategy, comprises highly promising targets for
such compounds.237
During P. falciparum proliferation, clearance of infected red
blood cells preceding the development of trophozoites with the
ability to intoxicate macrophages can occur as a result of
stimulation of suicidal erythrocyte death, eryptosis.238 Paclitaxel
(181, Figure 101) is an antitumoral agent used to treat different
types of cancers, and it is also known to cause eryptosis.239 In
this context, Koka et al. investigated whether this compound
influences eryptosis of P. falciparum-infected human eryth-
rocytes, in vitro parasite growth, and survival of P. berghei-
Figure 99. Structures of spiroazepineindole lead (177) and NITD609
(178).
Figure 100. Structures of Bay 43-9006 (179) and SU-11274 (180).
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infected mice.240 Results showed that paclitaxel actually
increased eryptosis of infected red blood cells and,
consequently, decreased in vitro growth of P. falciparum at
concentrations higher than 0.01 μM. In vivo, a significant
decrease in parasitemia was observed on P. berghei-infected
mice treated with the compound (intraperitoneal dose of 8.5
mg/kg during 12 days). Paclitaxel treatment increased the
survival of treated animals, with 69% of the infected mice
surviving the infection for more than 30 days. Despite the
encouraging results, further studies are needed to investigate if
paclitaxel could be an effective antimalarial in humans.
Heat shock proteins (HSP) are a class of highly conserved
molecular chaperones that facilitate protein folding.241 New
drugs that inhibit this class of proteins are reaching market
approval to treat cancer.242 In the specific case of P. falciparum,
heat shock protein 90 (Hsp90) has also been found essential
for parasite development during the intraerythrocytic cycle.243
Thus, in addition to their antitumoral potential, HSP inhibitors
have also been evaluated as competitive inhibitors of the ATP-
binding domain of P. falciparum Hsp90 and for their potential
as antimalarials.244 By screening about 4000 compounds, issued
from three different libraries, Shahinas et al. have identified 46
inhibitors of the P. falciparum Hsp90 ATP-binding domain.244
Harmine (182, Figure 102), a naturally occurring β-carboline
alkaloid with antitumoral activity, specifically inhibited the P.
falciparum Hsp90 ATP-binding domain compared to the
human Hsp90 ATP-binding domain.244,245 In addition, this
molecule also inhibited both sensitive (3D7) and resistant
(W2) P. falciparum strains with IC50 values of 50.1 and 28.0
nM, respectively, and demonstrated synergistic activity with
CQ.244 The previous use of harmine as antitumoral agent and
its potent antimalarial effect make this compound attractive for
further clinical development.
The inhibition of proteasome is reported to interrupt the
degradation of intracellular proteins that, in fast-proliferating
cancer cells, can lead to inhibition of cell cycle regulators and
cause apoptosis.246 The importance of proteasome inhibition as
a possible way to also treat parasitic diseases was highlighted by
several studies.247 Following this line of thought, Lindenthal
and co-workers found that MLN-273 (183, Figure 103), a
dipeptidyl boronic acid proteasome inhibitor, arrests the P.
falciparum erythrocytic cycle with IC50 values in the low
nanomolar range in both sensitive and drug-resistant
strains.247b Two other boronic acid dipeptides, bortezomib
(184, Figure 103), approved to treat multiple myeloma, and its
analogue ZL3B (185, Figure 103), were then reported as
potent inhibitors of four P. falciparum strains (3D7, HB3, W2
and Dd2) with IC50 values ranging between 31 and 45 nM.
248
Results showed that these boronate protease inhibitors
disrupted the cell cycle prior to DNA synthesis but had no
effect on parasite egress at the late schizont stage or subsequent
erythrocyte invasion.
In order to evaluate the antimalarial activity of some known
proteasome inhibitors, Kreidenweiss and co-workers tested a
few of these specific inhibitors, YU101, MG132, Ada-Ahx3-L3-
VS, Z-L3-VS and epoxomicin (Table 1), against CQ-resistant
(Dd2) and CQ-sensitive (3D7 and D10) P. falciparum
strains.249 The results showed that most of the inhibitors
presented antimalarial activity, with values of IC50 ranging from
1.7 to 4000 nM, with epoxomicin as the most effective against
the three P. falciparum strains (IC50 = 6.8 nM, 1.7 nM, and 10.4
nM for strains 3D7, D10 and Dd2, respectively). Later, it was
further demonstrated that the nanomolar concentrations of
epoxomicin effectively kill all stages of intraerythrocytic
parasites and block oocyst production in the mosquito
midgut.250 Although the MOA of these inhibitors is not clear
yet, the increased detection of ubiquitin conjugates after drugs
incubation suggests these compounds might target the
Plasmodium proteasome complex.247b
Salinosporamide A (186, Figure 104), a proteasome inhibitor
extracted from the marine actinomycete Salinospora tropica and
currently advancing through clinical trials as an antimyeloma
agent, was found to have an IC50 of 11.4 nM against P.
falciparum 3D7 strain.251 The effectiveness of this compound
against malaria parasites was further tested in vivo using the P.
yoelii mouse model. In agreement with in vitro data, infected
mice showed a significant decrease in parasitemia when treated
with salinosporamide A (130 μg/kg).251b Also, biochemical and
structural-based analyses validate the hypothesis of the
parasite’s 20S proteasome being the primary target of
salinosporamide A.251b Though no human clinical trials were
performed to confirm the effectiveness of proteasome inhibitors
against human malaria, targeting P. falciparum’s protein
degradation pathways has undeniably shown great promise,
Figure 101. Structure of paclitaxel (181).
Figure 102. Structure of harmine (182).
Figure 103. Structures of dipeptidyl boronic acids MLN-273 (183),
bortezomib (184) and ZL3B (185).
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suggesting the importance of the parasite’s proteasome in DNA
synthesis, cell cycle and parasite development.
In eukaryotes, histone acetyltransferases catalyze the transfer
of an acetyl group from acetyl-coenzyme A to the lysines’ side
chain ε-nitrogen, while histone deacetylases (HDAC) catalyze
the reverse reaction.252 Because these two processes have been
found to play critical roles in a variety of vital cellular functions,
such as DNA replication and repair, transcription, cell cycle
regulation and differentiation, and cell signaling, HDAC
enzymes are validated therapeutic targets for some types of
cancers.252,253 HDAC has also been shown as a crucial
transcription regulator in apicomplexan parasites.254 Since
then, several HDAC inhibitors have been found active against
Plasmodium parasites, as reported by reviews on the subject.255
For example, Chen et al. have discovered that suberoylanilide
hydroxamic acid, SAHA (187, Figure 105) and derivatives
present potent in vitro activity against sensitive (D6) and drug-
resistant (W2) P. falciparum strains.256 SAHA, clinically
approved to treat persistent or refractory T-cell lymphoma,
inhibits growth of P. falciparum D6 and W2 strains with IC50
values of 247 and 161 nM, respectively.256 One of SAHA’s
derivatives (188, Figure 105) was found to be about 14- and 5-
fold more active than its parent compound, with IC50 values of
17 and 32 nM for P. falciparum D6 and W2, respectively.
Table 1. IC50 Values of Some Proteasome Inhibitors against P. falciparum CQ-Sensitive (3D7 and D10) and CQ-Resistant
Strains (Dd2)
Figure 104. Structure of salinosporamide A (186).
Figure 105. Structures of SAHA (187) and its optimized triazole
derivative (188).
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Similarly, Marfurt et al. have disclosed that 2-aminosuberic-
based HDAC inhibitors present potent in vitro activity against
sensitive (3D7) and drug-resistant (K1) P. falciparum strains.257
The IC50 values for compounds 2-ASA-9 (189, Figure 106) and
2-ASA-14 (190, Figure 106) are, respectively, 15 nM and 13
nM against the 3D7 strain and 39 nM and 33 nM in the case of
the K1 strain. In the same study, the authors have also
discovered that these compounds highly inhibit maturation of
P. vivax schizonts, with IC50 values of 503 and 278 nM for 2-
ASA-9 and 2-ASA-14, respectively. These results greatly
encourage the development of potential candidates to treat
malaria in geographical regions where both P. falciparum and P.
vivax are endemic.
SB939 (191, Figure 107) is another example of hydroxamate-
based HDAC inhibitors with potent antimalarial activity, as
reported by Sumanadasa and co-workers.258 According to these
authors, this compound exhibited IC50 values of 80 and 150 nM
against 3D7 and Dd2 P. falciparum strains, respectively. In
addition, they also found that SB939 inhibited the growth of P.
berghei parasites within HepG2 liver cells with an IC50 of 150
nM. In vivo, when given orally (25 mg/kg twice a day for 3
days) to C57BL/6J mice, the compound significantly disrupted
parasite growth, protecting against experimental cerebral
malaria-like symptoms.258 Altogether, these results encourage
the development of HDAC inhibitors as a promising new class
of antimalarial agents.
Committed to better understand how malaria parasites force
the liver cells into submission on a molecular level, Kaushansky
and co-workers found that most of the changes caused by
Plasmodia in infected liver cells highly resemble changes
observed when normal cells convert into cancer cells.259 Using
protein lysate microarrays, they found that the pro-death
protein p53 was significantly decreased in infected hepatocytes,
meaning that the parasite could target this protein to foster
proliferation.259 Thus, the authors hypothesized that boosting
p53 activity could counteract its suppression, impeding parasite
survival. Nutlin-3 (192, Figure 108), a small molecule in clinical
development to treat several cancer types, induces apoptosis
and growth arrest in several cancer cell lines by selectively
binding to the p53-binding region of E3-ubiquitin ligase MDM-
2, thus preventing p53 degradation and, consequently,
increasing p53 levels.260 In this context, the authors have
confirmed that p53 levels were increased when HepG2 cells
were treated with nutlin-3 (20 μM) and that, once the treated
cell line was infected with P. berghei, liver-stage burden was
dramatically reduced.259 The in vitro results were further
supported by in vivo experiments; a dramatically lower liver-
stage parasite burden in BALB/cJ mice treated with nutlin-3
(daily dose of 50 mg/kg for 2 days) was observed .259 These
findings suggest that host pathways might constitute promising
targets for antimalarial prophylaxis.
The mammalian kinase target of rampamycin (mTOR) is
responsible for altering cellular lipid and protein synthesis as
well as autophagy, as a response to integrated signals from
oxygen, growth factors, energy, amino acids and stress.261 Some
mTOR inhibitors are being used in the treatment of cancer.262
In order to evaluate how inhibition of host mTOR signaling
would affect Plasmodium development, Hanson et al. have
tested torins, a structural class of mTOR inhibitors, against
liver- and blood-stage malaria parasites in vitro and in vivo.263
The results revealed that torin-2 (193, Figure 109) presented
an EC50 for asexual blood stage of 1.4 and 0.7 nM against P.
falciparum 3D7 and Dd2 strains. This compound was also
highly potent against in vitro development of liver stage P.
berghei (EC50 = 1.1 nM) and early P. falciparum gametocytes
(EC50 = 6.62 nM). Moreover, mice treated with a single oral
dose of torin-2 (10 mg/kg) presented a high reduction of
Plasmodium liver load. The same was observed when mice
infected with P. berghei-GFP sporozoites were treated with the
same dose of torin-2, while control mice became blood-stage
positive. It is noteworthy that torin-2 appears to have a novel
mode of action against Plasmodium parasites, distinct from its
ability to target human mTOR. Although the actual target of
torin-2 in the parasite is currently unknown, Hanson and co-
workers have demonstrated that its antimalarial activity is
Figure 106. Structures of 2-ASA-9 (189) and 2-ASA-14 (190).
Figure 107. Structure of SB939 (191).
Figure 108. Structure of nutlin-3 (192).
Figure 109. Structure of torin-2 (193).
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conferred by disrupting the dynamic trafficking of parasite
proteins, named upregulated in sporozoites 4 (UIS4) and
exported protein 1 (EXP1), to the parasitophorous vacuole
membrane inside the infected liver cell, inducing Plasmodium
elimination by the hepatocyte.
In summary, the sequencing of the P. falciparum’s genome
permitted researchers to access vital information such as
parasite’s putative proteins and what types of cellular functions
are important to the parasite’s biology. Subsequently, several
studies indicated that most of such crucial proteins and/or
cellular functions were well-established targets in other
pathologies, such as cancer, which resulted in the discovery
that many antitumoral agents are also able to impair malaria
parasite growth. These findings should stimulate both industry
and academia to further explore, at low cost, the potential of
r&r antitumoral drugs for malaria chemotherapy. However, it is
worth noting that although these reports are quite promising
regarding the development of antitumoral agents as antima-
larials, additional safety studies must be undertaken. Indeed,
antitumoral agents are generally considered to be toxic as, at
the concentration they are used, in addition to blocking cancer
cells, they also impair normal development of healthy cells. But,
according to Paracelsus’ law, “sola dosis facit venenum”; that is,
only the dose makes the poison. Therefore, after obtaining
potent in vitro activities against Plasmodia strains, it might be
possible that the antitumoral agents could be safely used at the
therapeutic window required for antimalarial action. Still, it is
imperative to confirm this possibility.
7.2. Antiretrovirals
In response to the HIV/AIDS pandemic in Africa, treatment
with antiretroviral agents started to be implemented in sub-
Saharan countries where HIV-1 is coendemic with malaria.264 A
short time later, evidence started to suggest that each disease
was affecting the outcome of the other, and following, it was
found that antiretrovirals decreased CD36 surface concen-
trations in vivo.265 It is known that mature-stage parasitized
erythrocytes adhere to endothelial cells in order to accumulate
in the microvasculature.266 Such adhesion is mediated by
interactions between various host receptors, such as CD36, and
P. falciparum erythrocyte membrane protein 1. In order to test
the hypothesis that impairment of CD36 function could
directly affect Plasmodium parasites and host interactions,
Nathoo and co-workers evaluated antiretroviral drugs on
nonopsonic phagocytosis by human macrophages and CD36-
mediated cytoadherence of parasitized erythrocytes.265b The
results showed that the protease-inhibitor class of antiretrovirals
particularly impaired both processes. Since then, several studies
were performed to test antiretrovirals against malaria, with the
hope of a possible repurposing of those drugs against this
parasitic disease.
For example, Skinner-Adams and co-workers reported that
the HIV-1 protease inhibitors ritonavir, saquinavir and indinavir
(correspondingly, 194−196 in Figure 110) were effective
against P. falciparum Dd2 in vitro at clinically relevant
concentrations (EC50 = 0.6, 0.4, and 1 μM, respectively).
267
Subsequently, other antiretroviral protease inhibitors were also
found to display potent antimalarial activity, such as lopinavir,
atazanavir and nelfinavir (correspondingly 197−199 in Figure
110).268 Parikh et al. reported that this latter compound
inhibited P. falciparum CQ-sensitive strains HB3 and D6 with
IC50 values of 1.4 and 2.0 μM, respectively, while IC50 values of
2.1 and 0.9 μM were observed for drug-resistant strains Dd2
Figure 110. Structures of ritonavir (194), saquinavir (195), indinavir (196), lopinavir (197), atazanavir (198) and nalfinavir (199).
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and W2, correspondingly.268b In addition, they also found that
lopinavir inhibits the P. falciparum’s aspartyl protease
plasmepsin II at a concentration (IC50 = 2.7 μM) near the
ones observed for disruption of cultured malaria parasites
growth. Although not as potent as lopinavir, atazanavir (IC50 =
3.3 and 13 μM) and nalfinavir (IC50 = 6.5 and 12.1 μM) were
also active against proliferation of P. falciparum W2 and
3D7.268a
Andrews et al. further investigated the effect of combining
some of the HIV-1 protease inhibitors mentioned above, in a
murine model of malaria.269 When P. chabaudi-infected mice
were treated orally twice daily for 8 days with ritonavir (10 mg/
kg)−lopinavir (40 mg/kg) or ritonavir−saquinavir (10 mg/kg
each), a significant attenuation of parasitemia and a delay in
potency were observed. The mechanism of antimalarial action
of these compounds was hypothesized to be inhibition of
parasite’s aspartyl proteases, plasmepsins.269 However, Parikh et
al. reported that, in contrast to what is observed with pepstatin
(known aspartic protease inhibitor), HIV-1 protease inhibitors
were more active against P. falciparum parasites knocked out
regarding their cysteine protease falcipain-2 than against wild-
type parasites, and not synergistic with E-64, a cysteine protease
inhibitor.270 In addition, the antiretroviral compounds were
equally active against parasites with knocked out plasmepsins
and wild-type parasites, suggesting that the antimalarial
mechanism of HIV-1 protease inhibitors differs from that of
pepstatin.270 To gain an understanding of how these
compounds impair parasite development, Peatey et al.
investigated their effects on individual stages of asexual
growth.271 Results showed that schizonts and trophozoites
were more sensitive to the compounds than earlier ring-stage
parasites. Taken together with the fact that all the drugs
inhibited gametocytogenesis, these findings suggest that the
primary target of these HIV-1 protease inhibitors is likely to be
expressed in both mature intraerythrocytic parasites and early
gametocytes.271
More recently, Grimberg et al. found that TMC-125 and
R278474 (correspondingly 200−201 in Figure 111), two HIV-
1 non-nucleoside reverse transcriptase inhibitors, presented
potent activity against P. falciparum W2 (IC50s of 0.5 and 1.1
μM, respectively).232 They hypothesized that the possible
target of these compounds could be a catalytic reverse
transcriptase component of the parasite’s telomerase, found
to be expressed in asexual blood-stages that have started DNA
synthesis.232 As telomerase activity seems to be necessary
during blood-stage parasite development, designing specific
antitelomerase molecules or screening other reverse tran-
scriptase inhibitors could lead to new antimalarial agents with
potent inhibition activity against proliferation of blood-stage
malaria parasites.
Overall, the fact that some antiretroviral agents also inhibit
malaria parasite growth suggests that HIV-infected individuals
being treated with antiretroviral drugs may also profit from an
antimalarial effect. Notice that most countries where malaria is
endemic also bear the burden of the HIV pandemic and have
increasing access to antiretroviral chemotherapy, making a
potential crossover between HIV and malaria treatments
undoubtedly important. However, further studies should be
performed in order to better understand the potential
interactions between therapies for these two infections.
8. FINAL REMARKS
Herein were reviewed representative works that, over the past
sesquidecade, have been focused on the discovery of new
antimalarial agents by building on already known molecular
scaffolds. Three main approaches were distinguished, (i) the
“chemical recycling” of classical drugs once considered as first-
line antimalarials but which became “fallen angels” of malaria
chemotherapy, (ii) the rescuing, for malaria, of known bioactive
molecules currently lacking clinical application, and (iii) the
repurposing, for malaria, of therapeutic agents in clinical use or
development against other diseases. Despite the time span and
subject restrictions imposed for the sake of conciseness, the
panoply of antimalarial hits, leads, and even candidates reported
as emerging from such approaches is quite remarkable. This
poses the question of how justified is the design, from scratch,
of novel drugs for a disease that majorly affects low-income
countries and some remote areas of the globe. Possibly the time
has come for a paradigm shift in antimalarial chemotherapy,
taking advantage of the huge plethora of known bioactive
compounds and active pharmaceutical ingredients (API), either
shelved or in clinical use, not necessarily related to malaria;
combining such chemical entities with already available high-
throughput whole-cell assays for malaria may provide a fast and
low-cost way to find antimalarial candidates whose synthesis
routes and physicochemical and pharmacokinetic properties
have been previously established. Hence, in analogy to the three
R’s of the environment, perhaps progress in antimalarial
chemotherapy should prioritize its own three R’s: recycle,
rescue, repurpose. After all, have not current first-line
artemisinin-based therapies emerged from the recycling of a
millenary antimalarial medicine?
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